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About this report
The Trends and developments report presents  
a top-level overview of the drug phenomenon in Europe, 
covering drug supply, use and public health problems 
as well as drug policy and responses. Together with 
the online Statistical bulletin, Country overviews and 
Perspectives on drugs, it makes up the 2013 European 
Drug Report package. 
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the hub of drug-related 
information in Europe. Its mission is to provide the EU 
and its Member States with ‘factual, objective, reliable 
and comparable information’ on drugs, drug addiction 
and their consequences. Established in 1993, it opened 
its doors in Lisbon in 1995 and is one of the EU’s 
decentralised agencies. With a strong multidisciplinary 
team, the agency offers policymakers the evidence 
base they need for drawing up drug laws and strategies. 
It also helps professionals and researchers pinpoint 
best practice and new areas for analysis. 
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5I Preface
This year, the EMCDDA’s annual analysis of the drug situation is presented in a new format. 
Consisting of a set of interlinked products, the European Drug Report (EDR) 2013 package 
aims to provide a common entry point to the work of the EMCDDA and allow different 
audiences easy access to the specific information they require. It provides an analysis 
that is more timely, interactive and interlinked. These developments are necessary to keep 
pace with both the rapidly shifting drug situation and the growing needs and changing 
expectations of our audiences.
Central to the EDR  package is this report (also available in print), which provides a top-level 
summary of trends and developments. The accompanying Perspectives on drugs (PODs) 
provide deeper insights into important issues, which this year include new treatment 
approaches for hepatitis C, high-risk cannabis use and the control of increasingly available 
new psychoactive substances. Additional layers to the package are provided by the 
Statistical bulletin and Country overviews, where national-level data and analysis can 
be found.
This approach coincides with the launch of a new EU drugs strategy for 2013–20, in 
which the European Union reaffirms its commitment to a balanced and evidence-based 
approach to drug issues. An important part of the EMCDDA’s mission is to help provide 
the information necessary to implement this strategy. Many of the positive developments 
surrounding drugs in Europe have been the result of a debate that has been informed by 
both an increasingly sound understanding of the problems and a scientifically rigorous 
assessment of the measures required to address them. We are proud of the part that the 
EMCDDA has played in this.
A set of interlinked elements allowing full access to the available data  
and analysis on the drugs problem in Europe
Trends and  
developments
providing a top-level  
analysis of key 
developments 
Statistical bulletin
containing full data 
arrays, explanatory 
graphics and 
methodological 
information 
Country overviews
national data  
and analysis at your 
fingertips 
Perspectives  
on drugs
interactive windows  
on key issues 
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However, we are also aware of the challenges that lie ahead. The EU drugs strategy will 
have to address a new policy landscape, many dimensions of which are elaborated in 
this report, including the necessary improvement of service provision for drug users in 
prison and the growing importance of synthetic drugs. The strategy will be implemented 
during a period of economic uncertainty and considerable global developmental and 
social change. Globalisation and technological innovation have an impact on all areas 
of modern life; not surprisingly, they affect the drug problems we face. As an information 
agency, we are responding to this with up-to-date and adaptable resources covering 
a broad perspective. We believe the EDR 2013, in both substance and form, represents an 
important step forward in addressing the challenges presented to us. Whether it is quick 
access to a strategic overview of the drug situation or an in-depth analysis of the statistical 
data that is required, we hope that the EDR 2013 will be a valuable and user-friendly 
access point for the considerable resources that are now available in this area.
João Goulão 
Chairman of the EMCDDA Management Board
Wolfgang Götz 
Director, EMCDDA


9I Introductory note and acknowledgements
This report is based on information provided to the EMCDDA by the EU Member States, the 
candidate countries Croatia and Turkey, and Norway. 
Statistical data reported here are for 2011, or the most recent year available. European 
totals and trends are based on those countries providing sufficient and relevant data 
for the period specified. The data analysis prioritises levels, trends and geographical 
distribution. The necessary technical caveats and qualifications of the data may be found 
in the English language online version of this report and in the EMCDDA Statistical bulletin 
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Summary
Today’s drug market appears to be more fluid and dynamic, 
and less structured around plant-based substances 
shipped over long distances to consumer markets in 
Europe. Globalisation and developments in information 
technology are important drivers here. Patterns of drug use 
in low and middle income countries are changing, and this 
may also have implications for Europe’s drug problems in 
the future. The Internet presents growing challenges, both 
as a mechanism for rapid diffusion of new trends and as 
a burgeoning anonymous marketplace with global reach. 
It creates a new interconnectedness in drug use and drug 
supply. It also, however, offers opportunities for finding 
innovative ways to deliver treatment, prevention and harm 
reduction interventions. 
The implications of these changes for public health are 
not yet fully understood. Signs that current policies have 
found traction in some important areas must be viewed in 
the light of an evolving drug situation, which will require 
adjustments to be made to current practices if they are to 
remain on target and fit for purpose. 
Old and new drug  
problems — the European  
landscape in 2013
The major features of the European 
drug landscape have remained 
relatively stable in recent years. 
Drug use remains high by historical 
standards, but positive changes can be 
seen, with record levels of treatment 
provision accompanied by some signs 
of erosion in injecting, new heroin use, 
cocaine consumption and cannabis 
smoking. Any optimism, however, 
must be tempered by concerns that 
youth unemployment and service 
cuts could lead to the re-emergence 
of ‘old’ problems. Moreover, a closer 
examination suggests that the drug 
situation may now be in a state of flux, 
with ‘new’ problems emerging that 
challenge current policy and practice 
models: new synthetic drugs and 
patterns of use are appearing, both on 
the illicit drug market and in the context 
of non-controlled substances. 
12
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The number of heroin users entering treatment for the 
first time also continues to fall, and overall those in heroin 
treatment are an ageing population. Opioid-related 
deaths have also decreased in recent years. Historically, 
heroin use has been characterised by injecting, but a 
long-term decline has been seen in this behaviour. This, 
together with the impact of interventions, is likely to have 
contributed to the decline seen in the number of new HIV 
infections attributed to drug use. A worrying observation 
here, however, is that recent HIV outbreaks related to 
drug injection in Greece and Romania have interrupted 
this positive trend. This emphasises the continued need 
to consolidate responses, especially with respect to 
harm reduction and effective drug treatment, if Europe 
is to continue to see a decrease in problems in this area. 
Regardless of any new trends in heroin use, the intractable 
nature of this problem means it will remain a key issue for 
drug services for many years to come. Faced with a large 
number of drug users now in contact with services, there 
is a growing need to focus on continuity of care, social 
reintegration services and building a consensus on what 
constitutes realistic long-term outcomes for recovery.
I Cocaine
Only a few countries report problems with crack cocaine 
use, and where this is found it often overlaps with the 
problematic use of other substances, including heroin. 
The use of powder cocaine is far more common but 
tends to be concentrated in a relatively small number of 
western European countries. Overall, both cocaine use 
and supply indicators have been trending downwards in 
recent years, and the dramatic decrease in the amount 
seized is probably influenced, in part, by organised crime 
groups diversifying trafficking routes and techniques. The 
Iberian Peninsula remains important for seizures, but 
proportionally less so than in the past, while reports of 
cocaine seizures in eastern Europe are worrying and raise 
questions about the potential for further diffusion of use.
I Cannabis
Despite some evidence of decreasing trends, especially 
in countries with a long and established history of high 
prevalence, cannabis use in Europe remains high by 
historical standards, with a large and relatively robust 
market existing for this substance. There is also increasing 
diversity in the types of cannabis products available. 
Herbal cannabis, sometimes of high potency, now plays 
a more important role, accompanied by the recent 
emergence of synthetic ‘cannabis-like’ products. Both 
are developments that are potentially worrying from a 
public health perspective. Given its status as the most 
commonly used drug, cannabis is an important issue for 
prevention work with young people, and in this area there 
is growing interest in the use of environmental prevention 
strategies. This reflects the evidence that suggests that 
environmental approaches have proved useful for reducing 
problems associated with the use of licit substances such 
as tobacco and alcohol.
Any positive changes in indicators of overall use of 
cannabis in Europe need to be understood in the context 
of a fairly heterogeneous situation at national level; for 
example, some countries consistently report low and 
stable prevalence levels, whereas the use of cannabis in 
many central and eastern European countries increased 
considerably during the 2000s. Trends also need to be 
viewed alongside different use patterns, with regular and 
long-term use being most associated with harm. Cannabis 
problems are now better recognised and understood in 
Europe; the drug represents the second most commonly 
reported substance for clients entering specialised drug 
treatment. While most cannabis treatment entrants tend 
to be male and relatively young, problems among older 
chronic users are becoming more recognised. 
Cannabis is also the drug that divides public attitudes, with 
some countries making an explicit distinction between 
cannabis and other substances in their drug control 
policies.
I Heroin and other opioids
Against the background of an overall increase in treatment 
availability for heroin users, indicators now suggest a 
downward trend in both use and availability of this drug. The 
long-term trend in the amount of heroin seized is downwards 
and, more recently, the number of seizures has also begun 
to fall. Some countries report that, over the last decade, 
heroin has been displaced from the market by other opioid 
drugs. Other countries have experienced more recent market 
shocks or shortages, generally followed by a partial recovery. 
 Against the background  
 of an overall increase  
 in treatment availability for  
 heroin users, indicators now 
 suggest a downward trend  
 in both use and availability  
 of this drug 
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further complications. A recent example is the emergence 
of the non-controlled stimulant substance 4-MA, which 
was first notified 2009, on the illicit drug market, either 
sold as or mixed with amphetamine. Clusters of deaths 
associated with this substance triggered a risk assessment 
exercise and subsequent recommendation for control at 
European level.
I New psychoactive substances
An increasing number of new psychoactive substances, 
often intended to mimic the effects of controlled drugs, 
can be found in Europe. Some substances are sold 
directly on the illicit market, while others, the so-called 
‘legal highs’ are sold more openly. Developments move 
rapidly in this area, with substances appearing at a fast 
rate. Occasionally a substance appears which makes 
the crossover to become a drug of choice on the illicit 
marketplace, the most recent example being mephedrone. 
The EU Early warning system continues to receive 
reports of around one new substance a week in 2013. 
Recent years have been dominated by the appearance 
of new synthetic cannabinoid receptor agonists (CRAs), 
phenethylamines and cathinones, mirroring to a large 
extent the most popular illicit drugs. A recent development, 
however, is an increasing proportion of substances 
reported that are from less known and more obscure 
chemical groups. Many of the products on sale contain 
mixtures of substances, and the lack of pharmacological 
and toxicological data means it is hard to speculate on 
long term health implications of use, but increasingly data 
shows that some of these substances cause problems 
requiring clinical interventions, and fatalities have been 
recorded.
The European Commission is preparing a new proposal 
for strengthening the EU response to new psychoactive 
substances. Although use of new psychoactive substances 
is seen mainly among young recreational users, there has 
been some diffusion into problem drug user populations. 
Some replacement of opioids by synthetic stimulants, 
especially cathinones, was noted in countries reporting 
heroin shortages. The motive for the transition from 
injecting heroin to cathinones is unclear, but may be linked 
to easy availability and perceived high quality of the new 
drugs. Public health concerns exist regarding increased 
levels of injection, mental health problems and physical 
damage. To date, countries have experimented with a 
range of control measures to respond to the new-drug 
problem. Less well developed, but equally important, is 
the need to identify and introduce appropriate demand 
reduction responses.
In the higher-prevalence countries, both survey and 
treatment entry data suggest a recent decline in cocaine 
use, although levels still remain high by historical 
standards. The number of deaths associated with cocaine 
use has fallen slightly, although caution is required when 
interpreting the data in this area. Acute problems related 
to the use of cocaine have resulted in presentations at 
hospital emergency departments in parts of Europe, but 
our capacity to monitor problems in this area is limited. In 
terms of treatment, specialist services are now available 
to problem cocaine users in many countries, with the 
current evidence base in this area supporting the use of 
psychosocial interventions.
I Synthetic stimulants
Understanding overall trends in the use of synthetic 
stimulant drugs is complicated by the fact that they are 
often substituted for each other, as consumers make 
choices influenced by availability, price and perceived 
‘quality’. Amphetamine and ecstasy remain the most 
commonly used synthetic stimulants in Europe and 
compete to some extent with cocaine. Amphetamine 
remains an important component of the drug consumption 
picture in many countries, and injecting amphetamine 
use has historically been a significant part of the chronic 
drug problem found in many northern countries. Over 
the longer term, most amphetamines indicators have 
remained stable; however, recent data suggest increasing 
methamphetamine availability, and in some markets 
this substance is now displacing amphetamine. Some 
evidence exists to suggest a decline over the last few years 
in the popularity of ecstasy, probably reflecting the fact 
that many pills sold as ecstasy did not contain MDMA or 
were of low purity. Recently, ecstasy producers appear to 
have become more efficient at sourcing MDMA and the 
content of tablets has correspondingly changed. It remains 
to be seen whether this will result in renewed interest in 
this drug, but there is some initial evidence that points in 
this direction. 
Stimulants, especially at high doses, can have adverse 
health consequences, and some deaths are reported 
annually. For stimulant users experiencing problems, 
their first point of contact with services will often be with 
hospital emergency departments. European projects are 
currently under way to improve monitoring of this area 
and provide guidelines on effective responses to drug 
emergencies in nightlife settings. Although stimulant-
related deaths are relatively uncommon, they do generate 
considerable concern, especially when they occur among 
young, otherwise healthy, adults. The emergence of new 
psychoactive substances with unknown toxicity adds 
 Reflecting its high prevalence of use,  
 cannabis is by far the most seized  
 drug in Europe 
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Chapter 1
Monitoring drug supply  
Analysis in this section is based on a range of data 
sources: drug seizures; dismantled drug production 
facilities; seizures of precursor chemicals; drug 
supply offences; retail drug prices, as well as 
forensic analyses of drug seizures. Full data sets and 
extensive methodological notes can be found in the 
Statistical bulletin. It should be noted that trends can 
be influenced by a range of factors which include law 
enforcement activity levels and the effectiveness of 
interdiction measures.  
Data on new psychoactive substances are based 
on notifications to the EU Early warning system, 
which relies on data provided by the EMCDDA’s and 
Europol’s national networks. A full description of this 
mechanism can be found on the EMCDDA website 
under Action on new drugs.
I One million seizures of illicit drugs in Europe
A substantial increase has been seen in the long-term 
trend in the number of seizures of illicit drugs made in 
Europe, with about one million seizures reported for 2011. 
Most of these were small quantities of drugs confiscated 
from users, although this total also includes multi-kilogram 
consignments seized from traffickers and producers. 
The majority of seizures in 2011 were reported by just 
two countries, Spain and the United Kingdom, however, 
Belgium and four Nordic countries also reported relatively 
high numbers. Another important country in respect to 
drug seizures is Turkey, with some of the drugs intercepted 
Europe is a major destination for 
controlled substances and also plays 
a limited role as a transit point for drugs 
en route to other regions. Latin America, 
West Asia and North Africa are important 
source areas for drugs entering Europe; 
however, the dynamics of the modern 
drug market mean that other regions 
of the world are now of growing 
importance. Europe is also a producing 
region for cannabis and synthetic drugs. 
While virtually all cannabis produced is 
intended for local consumption, some 
synthetic drugs are also manufactured 
for export to other regions.
The growing availability of ‘new 
psychoactive substances’ that are not 
controlled under international drug 
control treaties represents a relatively 
new development on European drug 
markets. Commonly produced outside 
of Europe, these substances can be 
obtained through online retailers, 
specialised shops, and are also 
sometimes being sold along with 
controlled substances on the illicit  
drug market.
Drug supply in Europe
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of all cannabis seizures (Figure 1.3). This reflects, in part, 
the growing availability of domestically produced herbal 
cannabis in many countries. The quantity of cannabis resin 
seized, however, although falling in recent years, is still 
much higher than the quantity of herbal cannabis reported 
(483 tonnes versus 92 tonnes in 2011). 
European trends in cannabis seizures have to be 
understood in the context that data from a limited number 
of countries are disproportionately important (Figure 1.4). 
Spain, for example, with its close proximity to Morocco, and 
substantial internal market, reported around two-thirds of 
the quantity of resin seized in Europe in 2011. In respect to 
herbal cannabis, Greece and Italy both reported recent large 
increases in quantities seized. Since 2007, Turkey has been 
the country seizing the largest quantities of herbal cannabis.
being intended for consumption in other countries, both in 
Europe and in the Middle East. 
Reflecting its high prevalence of use, cannabis is by far 
the most seized drug in Europe (Figure 1.1). Cocaine ranks 
second overall, with about double the number of seizures 
reported for either amphetamines or heroin. The number of 
ecstasy seizures is lower, and has declined considerably in 
recent years. FIGURE1
I Cannabis: changes in supply 
Two distinct cannabis products are commonly found on 
the European drugs market: herbal cannabis (‘marijuana’) 
and cannabis resin (‘hashish’). The annual consumption 
of these products can be roughly estimated at around 
2 500 tonnes. 
Herbal cannabis found in Europe is both cultivated 
domestically and trafficked from neighbouring countries, 
although some reports mention herb originating in 
other regions including Africa. Most cannabis resin is 
imported by sea or by air from Morocco. At European level, 
interceptions of resin are on average larger in size than 
those of herb. INFOGRAFIKA   FIGURE 1.2
Over the past ten years, the number of herbal seizures has 
overtaken that of resin, and now represents more than half 
FIGURE 1.1
Number of reported seizures by country (left), and proportion of seizures for the main drugs (right), 2011
Seizures (000s)   <1   1–10   11–100   >100   No data
NB: Numbers of seizures (in thousands) for the ten countries with highest values.
Cannabis resin 36%
Cocaine and crack 10%
Methamphetamine 1%Ecstasy 1%
Amphetamine 4%
Heroin 4%
Herbal cannabis 41%
Cannabis plants 3%
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100
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 Over the past ten years, 
 the number of herbal 
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345 000 seizures 398 000 seizures483 tonnes seized 92 tonnes seized
353 000 seizures including  
Turkey
439 000 seizures including  
Turkey
504 tonnes seized including Turkey 147
tonnes seized 
including Turkey
Price and purity of cannabis product: national mean values, minimum, maximum and interquartile range (IQR). 
Countries covered vary by indicator.
IQR
18 €
13 €
7 €
3 €
IQR
24 €
12 €
8 €
5 €
Price (EUR/g) Price (EUR/g)
Resin Herb
FIGURE 1.2
Predominant cannabis type, resin or herb, among number of seizures in 2001 and 2011
2001 2011
Resin: 51–75%   >75%   
Herb: 51–75%   >75%   No data 
61% of trafficking offencesfor the six main drugs
113 000 reported supply-related offences
Potency (% THC)
16%4%
11%5%
IQR
CANNABIS
Potency (% THC)
16%1%
5% 10%
IQR
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I Heroin: signs of a decline
Two forms of imported heroin have historically been 
available in Europe: the more common of these is brown 
heroin (its chemical base form), originating mainly from 
Afghanistan. Far less common is white heroin (a salt 
form), which historically came from South-East Asia, 
but now may be produced elsewhere. Some limited 
production of opioid drugs also still takes place in Europe, 
principally homemade poppy products reported in parts 
of eastern Europe. 
Seizures of cannabis plants can be regarded as an 
indicator of domestic production, although the quality of 
data available in this area poses problems for purposes 
of comparison. In 2011, 31 000 seizures of cannabis 
plants were reported in Europe. This includes reports of 
numbers of plants seized (4.4 million in total) as well as 
quantities (33 tonnes). The highest numbers of plants 
seized were reported by the Netherlands (2 million), Italy 
(1 million) and the United Kingdom (627 000), while Spain 
(26 tonnes) and Bulgaria (5 tonnes) reported the largest 
seizures by weight.
I  A new dimension: synthetic cannabinoid  receptor agonists
The recent availability of products containing synthetic 
cannabinoid receptor agonists (CRAs), which mimic the 
effects of the naturally occurring psychoactive compounds 
found in cannabis, adds a new dimension to the cannabis 
market. These products, which can be extremely potent, 
have now been reported in virtually all European countries. 
Multi-kilogram quantities in powder form are usually 
imported from Asia, with processing and packaging 
then occurring in Europe. Some evidence also exists of 
source chemicals being transited through Europe, such 
as a recent seizure of almost 15 kilograms of a pure CRA 
powder originating from China, but en route to Russia. 
FIGURE 1.3
Number of cannabis seizures, and quantity seized in tonnes: resin and herb, 2001–11
 The quantity of heroin seized 
 in 2011 was the lowest 
 reported in the last decade, 
 and equivalent to only 
 about half of the quantity 
 seized in 2001 
Number of seizures
 Resin
 Herb 
Herb (tonnes)
  Turkey   Other countries   United Kingdom  
 Spain   Greece   Italy   Netherlands
20052001 20062002 20072003 20082004 2009 2010 2011
20052001 20062002 20072003 20082004 2009 2010 2011
0
250 000
500 000
0
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500 000
Resin (tonnes)
  Spain   France   Other countries   Turkey  
 Italy   United Kingdom   Portugal
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1 200
1 000
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HEROIN    
12% of trafficking offencesfor the six main drugs
23 300 reported supply-related offences40 500 seizures6.1 tonnes seized
43 800 seizures including Turkey13.4
tonnes seized 
including Turkey
Price and purity of ′brown heroin′: national mean values, minimum,  
maximum and interquartile range (IQR). 
Countries covered vary by indicator.
44%6%
8% 15%
IQR
IQR
143 €
57 €
30 €
24 €
Purity (%) Price (EUR/g)
FIGURE 1.4
Quantity of cannabis resin (left) and herbal cannabis (right) seized, 2011
Resin Herb
Tonnes   <1   1–10   11–100   >100
NB: Amounts seized (in tonnes) for the ten countries with highest values.
356
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3
20
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2
5
2
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Afghanistan remains the world’s largest illicit producer of 
opium, and most heroin found in Europe is thought to be 
manufactured there or, to a lesser extent, in neighbouring 
Iran or Pakistan. Two loosely defined trafficking routes exist 
for transporting the drug to Europe: historically, the more 
important of these has been the ‘Balkan route’, running 
west through Turkey, into Balkan countries (Bulgaria, 
Romania or Albania) and on to central, southern and 
western Europe. A more recent trafficking route is the 
‘Northern’ or ‘Silk route’, which heads north to Russia, 
via the former Soviet republics of Central Asia. Generally, 
however, the situation now appears to have become 
more fluid, with heroin shipments from Iran and Pakistan 
entering Europe by air or sea, either directly or transiting 
through west and east African countries.   INFOGRAFIKA
20
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I Cocaine: changes in trafficking?
Two forms of cocaine are available in Europe, the most 
common of which is cocaine powder (a hydrochloride 
salt, HCl). Less commonly available is crack cocaine, 
a smokeable form of the drug. Cocaine is produced 
from the leaves of the coca bush. The drug is produced 
almost exclusively in Bolivia, Colombia and Peru and is 
transported to Europe by both air and sea routes. The main 
trafficking route into Europe appears to be through the 
Iberian Peninsula (Spain and Portugal), although increased 
use of container shipments means that the large ports of 
Belgium, the Netherlands and other western European 
countries may have gained in importance. Recent signs 
of the ongoing diversification of cocaine trafficking routes 
into Europe include large individual seizures in ports in 
Bulgaria, Greece, Romania, and Baltic countries. 
Not all cocaine reaches Europe in a form ready for 
marketing, and a number of illicit ‘laboratories’ have been 
dismantled in Europe in recent years. Spain detected and 
dismantled 73 facilities between 2008 and 2010, the 
majority of these were secondary extraction labs, used to 
extract cocaine from other materials in which it had been 
concealed, such as beeswax, fertiliser, plastic, foodstuffs 
or clothing.    INFOGRAFIKA
The quantity of heroin seized in 2011 (6.1 tonnes) was 
the lowest reported in the last decade, and equivalent to 
only about half of the quantity seized in 2001 (12 tonnes). 
The number of seizures reported over the same period 
(2001–11) also fell, from a peak of 63 000 in 2001, to an 
estimated 40 500 in 2011. To some extent, this drop may 
be explained by the growth of seizures between 2002 and 
2009 in Turkey, which has been consistently seizing more 
of the drug than all other countries combined since 2006 
(Figure 1.5). Substantial declines in quantities seized, 
however, have been reported in Turkey in 2010 and 2011.
In addition to the decline seen in heroin seizures and 
supply offences related to the drug, more acute short-
term market shocks, probably resulting from successful 
interdiction efforts on the Balkan route, have been reported 
recently. A number of countries with relatively large 
populations of heroin users experienced a significant 
heroin drought in late 2010 and early 2011, from which 
only some markets appear to have recovered.  FIGURE 1.5   
FIGURE 1.6
FIGURE 1.5 FIGURE 1.6
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This is similar to the quantity seized in the Netherlands and 
Belgium, which reported combined seizures of 18 tonnes of 
the drug in 2011. Record seizures of cocaine were reported 
in 2011 by France (11 tonnes) and Italy (6 tonnes). It is 
unclear to what extent the changes in quantities of cocaine 
seized in European countries reflect overall changes in 
supply to the European market, changes in law enforcement 
practices, or the introduction of new operational approaches 
by drug trafficking organisations. 
In 2011, around 86 000 seizures of cocaine were reported 
in Europe, amounting to 62 tonnes of the drug being 
intercepted. This represents an almost 50% fall from the 
120 tonnes of cocaine seized in the peak year 2006. The 
number of seizures has also fallen, but less markedly, having 
peaked at 100 000 seizures in 2008 (Figure 1.7). Decreases 
in the quantity of cocaine seized are most observable in the 
Iberian Peninsula, where the total intercepted by Spain and 
Portugal fell from 84 tonnes in 2006 to 20 tonnes in 2011. 
FIGURE 1.7 FIGURE 1.8
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I Amphetamines: signs of more methamphetamine
Initially developed for therapeutic purposes and generically 
known as amphetamines, methamphetamine and 
amphetamine are closely related synthetic stimulants. Of 
the two, amphetamine has always been the more common 
in Europe, but there are now signs of the increasing 
availability of methamphetamine.  2X     INFOGRAFIKA
Both drugs are manufactured in Europe for domestic use, 
although some amphetamine is also manufactured for 
exportation, principally to the Middle East. Production 
techniques can be relatively sophisticated, resulting 
in large production runs. The same equipment and 
personnel may also be used for the production of other 
synthetic substances such as MDMA (ecstasy). Significant 
production is known to take place in Belgium and the 
Netherlands, as well as in Poland and in the Baltic 
countries; labs have also been found in other countries, 
including Bulgaria, Germany and Hungary. A large number 
of methamphetamine production sites are reported by the 
Czech Republic, most of which are small-scale operations 
intended to provide drugs for the personal use of those 
involved although some larger-scale production has also 
been noted, with methamphetamine produced for both 
domestic consumption and export to bordering countries. 
Methamphetamine production in the Baltic countries 
also appears to have been scaled-up, with the drug being 
produced for export to Scandinavian countries, where it 
may be beginning to displace amphetamine. 
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FIGURE 1.9
Quantity of amphetamine (left) and methamphetamine (right) seized, 2011
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contrast, methamphetamine seizures, though still small in 
number and quantity, have increased over the same period 
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In 2011, about 45 000 seizures of amphetamines were 
reported. These can be broken down into 35 600 seizures 
and 5.9 tonnes of amphetamine, and 9 400 seizures 
amounting to 0.7 tonnes of methamphetamine. After a 
period of higher levels, both in terms of numbers and 
quantity, amphetamine seizures in 2011 have returned 
to about the same level found in 2002 (Figure 1.10). In 
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Ecstasy manufacture in Europe may have peaked in 
2000, when 50 laboratories were reported to have been 
dismantled. These decreased to three dismantled in 
2010 and five in 2011, suggesting that production levels 
across Europe have dropped. The Netherlands, followed by 
Belgium, have reported the highest numbers of dismantled 
laboratories over the last decade, and this is thought to 
reflect geographically the main production area for this drug. 
I Ecstasy: making a comeback?
Ecstasy usually refers to the synthetic substance MDMA, 
which is chemically related to amphetamines, but which 
differs to some extent in its effects. Tablets sold as 
ecstasy, however, may contain any of a range of MDMA-like 
substances and unrelated chemicals. 
FIGURE 1.10 FIGURE 1.11
Number of amphetamine seizures and quantity seized, 2001–11 Number of methamphetamine seizures and quantity seized, 2001–11
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Seizures of the drug have fallen sharply since 2007 
(Figure 1.12), and current figures of 4.3 million ecstasy 
tablets seized represent only a small fraction of what they 
were in the peak year of 2002 (23 million). A sharp drop 
has also been observed in drug supply offences related to 
ecstasy, which fell by about two-thirds between 2006 and 
2011, and now represent about 1% of offences related to 
the supply of the main drugs. These downward trends have 
been attributed to strengthened controls and the targeted 
seizure of PMK, the main precursor chemical for the 
manufacture of MDMA. This may also have been reflected 
in a substantial change in the contents of ‘ecstasy’ 
tablets available in Europe, with only three countries 
reporting that MDMA-like substances accounted for the 
largest proportion of tablets analysed in 2009. There are, 
however, indications of a recent resurgence of the ecstasy 
market, although not to the levels seen earlier. MDMA 
appears to be becoming more common, and high purity 
powder is available in parts of Europe. Ecstasy producers 
may have responded to precursor controls by moving 
to the use of ‘pre-precursors’ or ‘masked precursors’ 
— essential chemicals that can be legally imported as 
non-controlled substances and then converted into the 
precursor chemicals necessary for MDMA production.   
INFOGRAFIKA   FIGURE 1.12    FIGURE 1.13
FIGURE 1.13FIGURE 1.12
Quantity of ecstasy seized, 2011
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As the Internet is an important marketplace for new 
psychoactive substances, the EMCDDA undertakes a 
regular snapshot exercise to monitor the number of online 
shops offering products to European consumers. This 
number of shops identified continues to grow, with 693 
online shops identified in January 2012. 
After they are subjected to control measures, most new 
psychoactive substances tend to be rapidly replaced, 
making intervention measures particularly challenging 
in this area. Mephedrone, however, is a rare example of a 
new drug that may have made the crossover to become 
a sought-after substance on the illicit stimulant market. 
Despite controls across the European Union, the drug 
appears still to be available in some countries, where it is 
now sold on the illicit market. Although stocks obtained 
pre-ban may exist and clandestine importation may still 
take place, a worrying development is the recent discovery 
of a mephedrone production site in Poland, with links to 
international organised crime groups and evidence of 
trafficking to other European countries.
I New drugs: more substances available 
Analysis of the drug market is complicated by the 
emergence of new drugs (new psychoactive substances) 
— chemical or natural substances that are not controlled 
under international law, and produced with the intention 
of mimicking the effects of controlled drugs. In some 
cases, new drugs are produced in Europe in clandestine 
laboratories and sold directly on the market. Other 
chemicals are imported from suppliers, often in China or 
India, and then attractively packaged and marketed as 
‘legal highs’ in Europe. The term ‘legal highs’ is a misnomer, 
as substances may be controlled in some Member States, 
or if sold for consumption, contravene consumer safety 
or marketing regulations. To avoid controls, products are 
often mislabelled, for example as ‘research chemicals’ or 
‘plant food’ with disclaimers that state the product is not 
intended for human consumption. 
During 2012, 73 new psychoactive substances were 
notified by the Member States for the first time through 
the EU Early warning system (Figure 1.14). Reflecting 
consumer demand for cannabis-like products, 30 of 
these substances were synthetic cannabinoid receptor 
agonists. Nineteen compounds did not conform to the 
readily recognised chemical groups (including plants and 
medicines), while there were also 14 new substituted 
phenethylamines reported, the highest number since 2005. 
Number and main groups of new psychoactive substances 
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Monitoring drug use  
and drug-related problems
Monitoring of drug use and drug-related harms in 
Europe is based mainly upon five key epidemiological 
indicators: drug use among the general population, 
problem drug use, drug-related deaths and mortality, 
drug-related infectious diseases and drug treatment 
demand. Information on these indicators, including 
methodological notes can be found on the EMCDDA 
website under the Key indicators gateway and in the 
Statistical bulletin.
I  A quarter of European adults have used illicit drugs
At least 85 million adult Europeans have used an illicit 
drug at some point in their lives, representing around a 
quarter of Europe’s adult population. Most report having 
used cannabis (77 million), with much lower estimates for 
lifetime use of other drugs: 14.5 million for cocaine, 12.7 
million for amphetamines and 11.4 million for ecstasy. 
There is considerable variation in levels of lifetime drug use 
reported in Europe, ranging from around a third of adults in 
Denmark, France and the United Kingdom, to less than one 
in ten in Bulgaria, Greece, Hungary, Romania and Turkey.
Drug use and drug-related 
problems
Monitoring drug use and its associated 
harms is complicated by many factors. 
There is considerable variation in the 
ways in which illicit drugs are used, for 
example, with consumption patterns 
varying from the experimental and 
occasional to the daily and long-term. 
The risks that individuals are exposed 
to will also be mediated by numerous 
factors which include: the dose 
consumed, route of administration, 
the co-consumption of other 
substances, number and length of drug 
consumption episodes and individual 
vulnerability. 
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I  Cannabis: stable or decreasing trends in higher-prevalence countries 
Cannabis products are generally smoked and commonly 
mixed with tobacco. Patterns of cannabis use range 
from the occasional or experimental to the regular and 
dependent, with cannabis-related problems strongly 
associated with frequent use and higher amounts used. 
Health effects may include respiratory problems, mental 
health problems and dependence. Some of the new 
synthetic cannabinoid receptor agonists can be extremely 
potent, and acute adverse consequences are increasingly 
reported.
Cannabis is the illicit drug most likely to be tried by 
European students. In the 2011 ESPAD surveys, lifetime 
cannabis use among 15- to 16-year-olds ranged from 
5% in Norway to 42% in the Czech Republic (Figure 2.1). 
Gender ratios also varied, from unity to about 2.5 boys 
to each girl. In terms of the overall European trend, 
school students’ cannabis use increased between 1995 
and 2003, dropped slightly in 2007 and since then has 
remained stable. During this period, a noticeable trend 
has been a reduction in cannabis use in many of the 
countries that reported high levels of prevalence in early 
surveys. Over the same period, levels of cannabis use 
among school students increased in many of the countries 
in central and eastern Europe, showing a degree of 
convergence across Europe as a whole. In the six countries 
that have reported national school surveys undertaken 
after the ESPAD study (2011/12), prevalence of cannabis 
use among students remains stable or is slightly 
decreasing. FIGURE 2.1:
An estimated 15.4 million young Europeans (15–34) 
(11.7% of this age group) used cannabis in the last year, 
with 9.2 million of these aged 15–24 (14.9%). Cannabis 
use is generally higher among males. Longer-term trends 
among young adults are broadly in line with those for 
students, with gradual increases in use among some 
lower-prevalence countries, alongside decreases among 
higher-prevalence countries. With the exception of Poland 
and Finland, countries with recent surveys (2010 or later) 
report stable or decreasing trends among young adults 
(Figure 2.2). Few national surveys currently report on use 
of synthetic cannabinoid receptor agonists; for those that 
do, prevalence levels are generally low. FIGURE 2.2:
Lifetime prevalence of cannabis use among  
15- to 16-year-old school students
 
2011
NB: ESPAD data and national surveys for Spain and the United Kingdom. 
2003
2007
FIGURE 2.1
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preceding survey. Data from 22 countries, suggest that 
around 1% of adults, at least three million, report using 
the drug in this way. Over two-thirds of these are aged 
between 15 and 34 years, and in this age group, over 
three-quarters are male. INFOGRAFIKA
I  Over 3 million daily cannabis users and rising treatment demand
A significant minority of cannabis users consume the 
substance intensively. Daily or almost daily cannabis 
use is defined as use on 20 or more days in the month 
FIGURE 2.2
Percent   0–4   4.1–8   8.1–12   >12
Last year prevalence of cannabis use among young adults: selected trends (left) and most recent data (right)
NB: Trends for ten countries with the highest prevalence  
and three or more surveys.
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CANNABIS USERS IN TREATMENT
Smoking
as main route of 
administration
NB: Characteristics are for all treatment entrants with cannabis  
as primary drug. Trends are for first-time treatment entrants with  
cannabis as primary drug. Countries covered vary by indicator.
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I  Illicit stimulants in Europe: regional patterns of use 
Cocaine, amphetamines and ecstasy are the most 
commonly used illicit stimulants in Europe, while some 
lesser-known substances, including piperazines (e.g. BZP) 
and synthetic cathinones (e.g. mephedrone and MDPV), 
may also be used illicitly for their stimulant effects. High 
levels of stimulant use tend to be associated with specific 
dance, music and nightlife settings, where these drugs are 
often used in combination with alcohol. 
Prevalence data illustrate the geographically divergent 
stimulant market in Europe, with cocaine more prevalent 
in the south and west of Europe, amphetamines more 
common in central and northern countries, and ecstasy 
the most prevalent stimulant in countries in the south and 
east (Figure 2.3). Treatment data show similar patterns for 
cocaine and amphetamine, while the numbers entering 
treatment for ecstasy problems are low. FIGURE 2.3
In 2011, cannabis was the second most frequently 
reported primary drug, after heroin, for clients entering 
specialised drug treatment in Europe (109 000) and the 
most frequently mentioned drug among those entering 
treatment for the first time. However, considerable national 
variation can be seen, ranging from 4% of all drug clients 
reporting this drug as a reason for entering treatment in 
Bulgaria to 69% in Hungary. These differences can be 
explained by differences in referral practices, the type 
of treatment services available and national prevalence 
levels. Europe has seen the numbers of cannabis clients 
entering treatment for the first time increase from about 
45 000 in 2006 to 60 000 in 2011.
FIGURE 2.3
Predominant stimulant drug by last year prevalence among 15- to 34-year-olds (left) and by primary drug in first-time treatment entrants (right)
 Cocaine   Amphetamines   Ecstasy   No data
 Cannabis... the most 
 frequently mentioned drug 
 among those entering 
 treatment for the first time 
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I  Cocaine: decreasing use in high  prevalence countries
Cocaine powder is primarily sniffed or snorted, but is 
also sometimes injected, while crack cocaine is usually 
smoked. Among regular users, a broad distinction can 
be made between more socially integrated consumers, 
who may be using the drug in a recreational context, and 
more marginalised drug users, who use cocaine, often 
along with other substances, as part of a chronic drug 
problem. Regular cocaine use has been associated with 
cardiovascular, neurological and mental health problems, 
and with an elevated risk of accident and dependence. 
Cocaine injection and crack use are associated with 
the highest health risks, including the transmission of 
infectious diseases.FIG 2.4: 
 Cocaine, amphetamines  
 and ecstasy are the most 
 commonly used illicit  
 stimulants in Europe 
FIGURE 2.4
Percent   0–1   1.1–2   2.1–3   >3   No data
Last year prevalence of cocaine use among young adults: selected trends (left) and most recent data (right)
NB: Trends for ten countries with the highest prevalence  
and three or more surveys.
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Cocaine was cited as the primary drug for 14% of all 
reported clients entering specialised drug treatment in 
2011 (60 000), and 19% of those entering treatment for 
the first time (31 000). Wide differences exist between 
countries, with around 90% of all cocaine clients being 
reported by only five countries (Germany, Spain, Italy, 
Netherlands, United Kingdom). The number of clients 
entering treatment for the first time in their life for 
primary cocaine use increased from 35 000 in 2006 
to 37 000 in 2009 and then decreased to 31 000 in 
2011 (23 countries). Spain has seen a small, but steady 
reduction in numbers of new cocaine clients entering 
treatment since 2005, the United Kingdom since 2008 and 
Italy since 2009. Only about 3 000 new primary users of 
crack cocaine entered treatment in Europe in 2011, with 
the United Kingdom accounting for around two-thirds of 
these, and Spain and the Netherlands most of the rest. 
I  Longer-term increase in cocaine hospital emergencies 
A recent European review identified a threefold increase in 
indicators of cocaine-related hospital emergencies in some 
countries since the end of the 1990s, with a peak observed 
around 2008 in Spain and the United Kingdom (England). 
Most cocaine-related emergencies occurred among young 
males. Deaths caused by acute cocaine poisoning seem 
to be relatively uncommon. In 2011, at least 475 deaths 
Cocaine is the most commonly used illicit stimulant drug 
in Europe, although most users are found in a relatively 
small number of countries. It is estimated that about 
2.5 million young Europeans (1.9% of this age group), 
used cocaine in the last year. Relatively high levels of 
last year cocaine use among young adults (2.5–4.2%) 
were reported by Denmark, Ireland, Spain and the United 
Kingdom (Figure 2.4). In the higher-prevalence countries 
with more recent surveys, levels of last year cocaine use 
among young adults tended to peak in 2008/09 and have 
subsequently shown modest declines or stabilisation. 
In other countries, levels of cocaine use have remained 
relatively low and stable, although France and Poland both 
reported increases in 2010.   INFOGRAFIKA 
I  Signs of decline in cocaine  treatment demand 
Only four countries have relatively recent estimates of 
intensive or problem cocaine use, and these are difficult to 
compare, as the definitions used differ. In 2009, among the 
adult population: Spain estimated ‘intensive cocaine use’ 
at 0.45%; Germany estimated ‘cocaine-related problems’ 
at 0.20%; and Italy produced an estimate of 0.34% for 
‘potentially problem cocaine use’. For 2009/10, the United 
Kingdom estimated crack cocaine use among the adult 
population in England at 0.54%, but noted that many of 
these were likely to be both crack and opioid users. 
COCAINE USERS IN TREATMENT
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diseases. Deaths related to amphetamines, though rare in 
comparison to those related to opioid drugs, are reported 
by some countries, particularly those with relatively large 
amphetamine-using populations. Overdoses due to 
amphetamines may, however, be more difficult to identify, 
as the symptoms may be less specific. This problem is 
complicated by the emergence of new stimulant drugs. 
For example, over 20 fatalities in 2011 and 2012 have 
been associated with the amphetamine-related compound 
4-methylamphetamine, prompting the EMCDDA and 
Europol to undertake a European-level risk assessment, 
and the European Commission to recommend EU-wide 
control measures. FIGURE 2.5: 
related to cocaine were reported in 17 countries, although 
other drugs were also often present. Recent data from 
Spain and the United Kingdom suggest a decrease in 
cocaine-related deaths since 2008. Cocaine is also likely 
to play a role in some deaths related to cardiovascular 
problems, but data in this area are limited. 
I  Amphetamines: use stable but health risks continue
In Europe, amphetamine is more widely available than 
methamphetamine, use of which has historically been 
restricted to the Czech Republic and, more recently, 
Slovakia. Amphetamines are usually taken orally or 
snorted, but in a few countries, injection of these drugs 
is relatively common among problem drug users and 
treatment clients. 
Most studies on adverse health effects linked with 
amphetamines use are from Australia and the United 
States, where crystal methamphetamine smoking 
is prevalent, and their findings may not be directly 
transferable to the European situation. These studies 
identify effects including cardiovascular, pulmonary, 
neurological and mental health problems, ranging from 
anxiety, aggression and depression, to acute paranoid 
psychosis, while injection is a risk factor for infectious 
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FIGURE 2.5
Last year prevalence of amphetamines use among young adults: selected trends and most recent data 
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as the primary drug by a large proportion of first-time 
clients in the Czech Republic and Slovakia. Between 
2006 and 2011, trends for amphetamines users 
entering treatment for the first time largely remained 
stable, with the exception of the Czech Republic and 
Slovakia, which reported increased numbers of first-time 
methamphetamine clients. 
I  Ecstasy: low treatment demand
Ecstasy usually refers to the synthetic substance MDMA. 
The drug is mostly used in tablet form, but is sometimes 
available as a powder; it can be swallowed, snorted or 
(rarely) injected. Ecstasy use has historically been linked 
to the electronic dance-music scene, and is concentrated 
among young adults, particularly young males. 
Problems associated with use of this drug include acute 
hyperthermia and mental health problems. Ecstasy-related 
deaths are rare.
It is estimated that 1.8 million young adults used ecstasy 
in the last year, with national estimates ranging from under 
0.1% to 3.1%. Consumption of the drug typically peaked 
in the early to mid 2000s, before declining (Figure 2.6). 
Between 2006 and 2011, most countries have reported 
stable or declining trends in ecstasy use. With the 
exception of Poland, this decline continues to be seen in 
data from countries reporting surveys since 2010. Few 
users entered treatment for problems relating to ecstasy 
An estimated 1.7 million (1.3%) young adults (15–34) 
used amphetamines during the last year. Between 2006 
and 2011, last year amphetamines use remained relatively 
low and stable among young adults in most European 
countries, with prevalence levels of around 2% or less 
in all reporting countries with the exception of Bulgaria 
(2.1%), Estonia (2.5%) and Poland (3.9%). Among the 
countries with recent surveys (2010 or later), all reported 
stable or decreasing amphetamine prevalence levels, 
with the exception of Poland, which reported an increase 
(Figure 2.5).  INFOGRAFIKA
I  Increase in methamphetamine treatment demand 
Only two countries have recent estimates of the number 
of problem methamphetamine users, with estimates for 
adults (15–64) of around 0.42% for the Czech Republic 
(2011) and about 0.21% in Slovakia (2007). Indications of 
problem methamphetamine use have recently been noted 
in Germany, Greece, Cyprus and Turkey.
Around 6% of clients entering specialised drug treatment 
in Europe in 2011 report amphetamines as their primary 
drug (approximately 24 000 clients, of whom 10 000 
entered treatment for the first time in their life). Primary 
amphetamine users account for a sizeable proportion 
of reported first-time treatment entries only in Latvia, 
Poland and Sweden, while methamphetamine is cited 
AMPHETAMINES USERS IN TREATMENT
Trends in first-time entrantsCharacteristics
29% 71%
19Mean age at first use
28Mean age at treatment entry
Frequency of use
  Daily
  Two to six times a week
  Once a week or less
  Not used in the last month/ 
occasional
25%
26%
19%
23%
33%
1%
42%
6%
25%
Main route of administration
  Injecting
 Smoking
  Eating/drinking
 Sniffing
 Other
NB: Characteristics are for all treatment entrants with amphetamines as 
primary drug. Trends are for first-time treatment entrants with amphetamines 
as primary drug. Countries covered vary by indicator.
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in 2011: ecstasy was mentioned as the primary drug by 
less than 1% (around 600 clients) of reported first-time 
treatment entrants in Europe.  FIG 2.6
I  Mephedrone: new contender on the stimulant market
There are signs that synthetic cathinones, including 
mephedrone, may have carved a space in the illicit 
stimulants market in some countries. At present, however, 
only the United Kingdom has repeat surveys that include 
these drugs. In the most recent data, 1.1% of adults 
(16–59) in England and Wales reported using mephedrone 
in the last year, making it the fourth most commonly used 
illicit drug. Among 16- to 24-year-olds, last year prevalence 
was the same as that of ecstasy (3.3%), the third most 
prevalent drug among this age group. A decrease in levels 
of use, however, was noted for all groups compared with 
the 2010/11 survey. 
More generally, mephedrone-related mortality and 
morbidity continue to be reported in Europe, although 
at relatively low levels. Some countries also report the 
injection of mephedrone, MDPV and other synthetic 
cathinones, among groups of problem drug users and  
drug treatment clients (Hungary, Austria, Romania,  
United Kingdom). 
 Synthetic cathinones,  
 including mephedrone,  
 may have carved a space  
 in the illicit stimulants  
 market in some countries 
FIGURE 2.6
Last year prevalence of ecstasy use among young adults: selected trends (left) and most recent data (right)
NB: Trends for ten countries with the highest prevalence  
and three or more surveys. 
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central and eastern Europe in the mid to late 1990s. 
Although trends have varied over the last decade, overall, 
new recruitment into heroin use now appears to be on the 
decline. 
The average prevalence of problem opioid use among 
adults (15–64) is estimated at 0.41%, the equivalent of 
1.4 million problem opioid users in Europe in 2011. At 
national level, prevalence estimates of problem opioid 
use vary between less than one and around eight cases 
per 1 000 population aged 15–64 (Figure 2.7).  FIGURE 
2.7 FIGURE 2.8
I  Hallucinogens, GHB and ketamine: still in the picture
A number of psychoactive substances with hallucinogenic, 
anaesthetic and depressant properties are available on the 
illicit drug market in Europe: these may be used on their 
own, alongside, or in place of other more common drugs. 
The overall prevalence levels of hallucinogenic mushrooms 
and LSD use in Europe have been generally low and stable 
for a number of years. Among young adults (15–34), 
national surveys report last year prevalence estimates for 
the use of hallucinogenic mushrooms ranging from 0% to 
2.2%, and for LSD from 0% to 1.7%. 
Since the mid 1990s, recreational use of ketamine and 
gamma-hydroxybutyrate (GHB) has been reported among 
subgroups of drug users in Europe. Recognition is growing 
of the health problems related to these substances, for 
example, damage to the urinary tract associated with 
long-term ketamine use. Loss of consciousness and 
dependence are risks linked to use of GHB, and withdrawal 
syndrome has been documented. Where they exist, 
national estimates of the prevalence of GHB and ketamine 
use in both adult and school populations remain low. In the 
United Kingdom, 1.8% of 16- to 24-year-olds reported last 
year ketamine use, with levels remaining stable between 
2008 and 2012, although increasing from 0.8% in 2006. 
Targeted surveys in nightlife settings report higher levels 
of lifetime prevalence, for example, a survey among Danish 
clubbers reported 10% had tried ketamine. Among UK 
respondents to an Internet survey who were identified as 
regular clubbers, 40% reported last year use of ketamine 
and 2% last year use of GHB. 
I  Opioids: more than 1.4 million problem users
Use of opioids remains responsible for a disproportionately 
large share of the mortality and morbidity resulting from 
drug use in Europe. The main opioid used in Europe is 
heroin, which may be smoked, snorted or injected. A 
range of other synthetic opioids, such as buprenorphine, 
methadone and fentanyl, are also available on the illicit 
market. Most opioid users are polydrug users, and 
prevalence figures are higher in urban areas and among 
marginalised groups. In addition to health problems, opioid 
users entering treatment generally report higher levels 
of homelessness and unemployment and lower levels of 
education compared with users of other drugs.
Europe has experienced different waves of heroin 
addiction, the first affecting many western European 
countries from the mid 1970s and a second wave affected 
National estimates of prevalence of problem opioid use  
and injecting drug use
FIGURE 2.7
NB: Data displayed as point estimates and uncertainty intervals.
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Estimates of problem opioid use in Europe
FIGURE 2.8
 New recruitment into  
 heroin use now appears  
 to be on the decline 
I  Heroin: decline in new clients  entering treatment 
Users of opioids (mainly heroin) represent 48% of all 
clients who entered specialised treatment in 2011 in 
Europe (197 000 clients) and around 30% of those 
entering treatment for the first time. In terms of trends, 
overall numbers of new heroin clients are on the decline in 
Europe, dropping from a peak of 59 000 in 2007 to 41 000 
in 2011 and with reductions most apparent in western 
European countries. Overall, it appears that recruitment 
into heroin use may have been in decline, and that this is 
now impacting on treatment demand. INFOGRAFIKA
HEROIN USERS IN TREATMENT
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NB: Characteristics are for all treatment entrants with heroin as primary 
drug. Trends are for first-time treatment entrants with heroin as primary drug. 
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I  Injecting drug use: long-term decline 
Injecting drug users are among those at highest risk of 
experiencing health problems from their drug use, such 
as blood-borne infections or drug overdoses. Injection is 
commonly associated with opioid use, although in a few 
countries, amphetamines injection is a major problem. 
Thirteen countries have recent estimates of the prevalence 
of injecting drug use, ranging from less than one to 
approximately six cases per 1 000 population aged 15–64. 
Among clients entering specialised treatment, 38% of opioid 
clients and 24% of amphetamines clients report injecting 
the drug. Levels of injecting among opioid clients vary 
between countries, from less than 9% in the Netherlands 
to more than 93% in Latvia. Between 2006 and 2011, there 
has been an overall decrease in the proportion of injectors 
among heroin clients entering drug treatment for the first 
time; the most recent data, however, show a small upturn. 
I  Opioids other than heroin:  a challenge in some countries
In 2011, eleven European countries reported that 10% or 
more of their first-time opioid clients entering specialised 
treatment were using opioids other than heroin, including 
fentanyl, methadone and buprenorphine (Figure 2.9). 
In some countries, these drugs now represent the most 
common form of opioid use: in Estonia, the majority of 
treatment entrants for opioids were using illicit fentanyl, 
while in Finland most opioid clients are reported to be 
primary users of buprenorphine. FIG 2.9
FIGURE 2.9
First-time treatment entrants for opioids other than heroin: trends in numbers (left) and as a percentage  
of all first-time entrants with opioids as primary drug (right)
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I  Outbreaks threaten long-term  decline in HIV
The injection of drugs continues to be an important 
mechanism for the transmission of infectious diseases, 
including HIV/AIDS and hepatitis C. The latest figures 
show that the long-term decline in the number of new 
HIV diagnoses in Europe might be interrupted as a result 
of outbreaks among injecting drug users in Greece and 
Romania (Figure 2.10). In 2011, the average rate of newly 
reported HIV diagnoses attributed to injecting drug use 
was 3.03 per million population. Although the figures are 
subject to revision, there were 1 507 newly reported cases 
in 2011, slightly more than in 2010, disrupting the overall 
downward trend observed since 2004. 
The European figure masks important differences in 
levels and trends in new diagnoses of HIV in individual 
countries. In 2011, Greece and Romania accounted for 
353 diagnoses, or 23% of the total, whereas in 2010 these 
countries represented just over 2% (31/1 469). Bulgaria, 
Estonia and Latvia reported slight increases in rates of 
newly diagnosed HIV infections among injecting drug 
users in 2011, while in contrast, the rates reported by 
Ireland, Spain and Portugal all continued to fall, in line with 
the downward trend observable since 2004. FIG 2.10, 2.11
Newly diagnosed HIV infections related to injecting drug use: selected trends (left) and most recent data (right) 
FIGURE 2.10
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NB: Newly diagnosed HIV infections among injecting drug users in countries 
reporting the highest rates in 2011 (source: ECDC).
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I  Hepatitis and other infections:  major health issues 
Viral hepatitis, in particular infection caused by the 
hepatitis C virus (HCV), is highly prevalent among injecting 
drug users across Europe. HCV antibody levels among 
national samples of injecting drug users in 2010–11 
varied from 18% to 80%, with eight of the 12 countries 
with national data reporting a prevalence rate in excess 
of 40% (Figure 2.11). Prevalence at or above this level 
may indicate that a potential exists for new outbreaks of 
injecting-related HIV transmission. Among countries with 
national trend data for the period 2006–11, declining 
HCV prevalence in injecting drug users was reported in 
three countries (Italy, Portugal, Norway), while two others 
observed an increase (Greece, Cyprus). 
Averaged across the 18 countries for which data are 
available for the period 2010–11, injecting drug use 
accounts for 58% of all HCV diagnoses and 41% of the 
acute diagnoses notified (where the risk category is 
known). For hepatitis B, injecting drug users represent 
7% of all diagnoses and 15% of acute diagnoses notified. 
Drug use may be a risk factor for other infectious diseases 
including; hepatitis A and D, sexually transmitted diseases, 
tuberculosis, tetanus, and botulism. Outbreaks of anthrax 
infection, probably caused by contaminated heroin, are 
also sporadically reported in Europe. For example, between 
June 2012 and early March 2013, 15 drug-related anthrax 
cases were reported, of which seven resulted in fatalities. 
This may be related to an earlier outbreak of anthrax cases 
reported in 2009/10.   FIG 2.11
I  Drug-related deaths: not only overdoses 
Drug use is one of the major causes of mortality among 
young people in Europe, both directly through overdose 
(drug-induced deaths) and indirectly through drug-related 
diseases and accidents, violence and suicide. Most studies 
on cohorts of problem drug users show mortality rates 
in the range of 1–2% per year, representing an excess 
mortality 10 to 20 times greater than expected. A recent 
EMCDDA analysis estimated that between 10 000 and 
20 000 opioid users die each year in Europe. Most of these 
deaths occur among males in their thirties; however, age, 
mortality rates, and causes of death vary across countries 
and time. 
HIV-related mortality is the best documented indirect 
cause of death among drug users. The most recent 
estimate suggests that about 1 700 people died of HIV/
AIDS attributable to injecting drug use in Europe in 2010, 
and the trend is downward. Liver disease is also likely to 
account for considerable numbers of deaths among drug 
users, mainly due to HCV infection, and often worsened 
by heavy alcohol use, though European figures are not 
available. Suicide, injuries and homicide also have an 
impact on excess mortality among drug users although 
again reliable estimates are lacking. 
The main cause of death among problem drug users in 
Europe is drug overdose, and opioids, mainly heroin or 
its metabolites, are present in the majority of reported 
cases, often in combination with other substances such 
as alcohol or benzodiazepines. In addition to heroin, other 
opioids found in toxicological reports include methadone, 
buprenorphine and fentanyls. 
Approximately 90% of overdose deaths reported in Europe 
occur among those aged over 25 years, and the average 
age of those dying from overdoses is rising, suggesting 
an ageing cohort of problem opioid users. Most overdose 
deaths (80%) are reported among men. 
HCV antibody prevalence among injecting drug users, 2010/2011
FIGURE 2.11
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Drug-induced mortality rates 
among adults (15–64) For 2011, the average mortality rate due to overdoses in 
Europe is estimated at 18 deaths per million population 
aged 15–64. Rates of over 40 deaths per million were 
reported in six countries, with the highest rates reported 
in Norway (73 per million) and Estonia (136 per million) 
(Figure 2.12).
Most countries reported an increasing trend in overdose 
deaths from 2003 until 2008/09, when overall levels first 
stabilised and then began to decline. Overall, around 6 500 
overdose deaths were reported in 2011, a decrease from 
the 7 000 cases in 2010 and 7 700 in 2009. Nevertheless, 
the situation varies for individual countries, with some still 
reporting increases.  FIG 2.12
 Around 6 500 overdose  
 deaths were reported  
 in 2011, a decrease from  
 the 7 000 cases in 2010  
 and 7 700 in 2009 
FIGURE 2.12
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Monitoring drug-related responses
Responses to drugs are currently monitored 
using a combination of routine data sources and 
national assessments and expert ratings. Health 
and social responses data include estimates on 
the provision of opioid substitution treatment and 
needle and syringe provision. In addition, reviews of 
scientific evidence, such as those provided by the 
Cochrane Collaboration, provide information on the 
effectiveness of public health interventions. Further 
information on the data presented here and on the 
evidence base for responses can be found on the 
EMCDDA website in the Statistical bulletin and the 
Best practice portal. 
I  Progress towards evidence-based  prevention in schools
A number of prevention strategies are used to tackle 
drug use and drug-related problems. Environmental and 
universal approaches target entire populations, selective 
prevention targets vulnerable groups and indicated 
prevention focuses on at-risk individuals. In Europe, 
most prevention activity tends to take place in schools 
(Figure 3.1), although it is also implemented in other 
settings.
Responding to drugs
Drug-related responses may be 
broadly categorised as either drug 
demand reduction or drug supply 
reduction activities. The former includes 
health and social interventions, 
such as prevention, harm reduction, 
treatment and social reintegration. 
The latter includes the enforcement 
of drug-related legislation, mainly by 
police, customs and the judiciary,  
with a primary aim of reducing the 
availability of drugs. 
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Evidence suggests that environmental prevention 
strategies, which aim at altering cultural, social, physical 
and economic environments, can be effective in changing 
normative beliefs and, consequently, substance use. In 
Europe as a whole, the use of environmental interventions 
in school settings remains rare. In some areas, however, 
such as the promotion of protective school climates and 
the development of school drug policies (e.g. guidelines 
on responding to use or sale of drugs by pupils), progress 
has been made. A small shift has also been noted towards 
the use of positively evaluated universal prevention 
approaches in schools, such as personal and social skills 
training, and a move away from activities such as basic 
information provision, where the evidence for effectiveness 
is weak. There has been an increasing number of reports 
of the successful transfer of positively evaluated North 
American and European prevention programmes (e.g. 
Good Behaviour Game, EUDAP (Unplugged), Örebro and 
Preventure). 
Selective prevention interventions target vulnerable 
groups of young people who may be at greater risk of 
developing drug use problems. Expert reports indicate an 
overall increase in the availability of interventions for some 
vulnerable groups in Europe, in particular increased activity 
geared towards pupils with social and academic problems. 
Schools also represent an important setting for indicated 
prevention activities, including the use of approaches 
geared towards the early identification of pupils with 
behavioural and drug problems. FIGURE 3.1
I  Interventions in nightlife settings: the need for an integrated approach
The use of illicit drugs, particularly stimulants, is known 
to be associated with nightlife settings, and young people 
attending some types of events may engage in patterns 
of drug and alcohol use that can place them at a high 
risk of experiencing health problems, accidents or injury. 
A European initiative, the Healthy Nightlife Toolbox, 
emphasises the importance of ensuring that recreational 
settings have a comprehensive set of measures in place 
to address these risks; the recommended approach 
integrates prevention, harm reduction, regulation and law 
enforcement interventions. 
The use of prevention and harm-reduction strategies in 
recreational settings is reported by just over a third of 
countries. Some of these strategies target individuals, 
through the distribution of information leaflets, peer 
education interventions and use of mobile teams. 
Other strategies have an environmental focus: for 
example, regulating and licensing premises that sell 
Availability of specific drug prevention interventions in schools 
(expert ratings, 2010)
Early identification  
approaches
Interventions for social and  
academic problems
School drug  
policies
FIGURE 3.1
 Full/extensive   Limited/rare   Not available   No data
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alcohol; promoting the responsible serving of alcohol; 
implementing crowd management initiatives, and ensuring 
access to free water and safe late-night transport. Such 
measures are promoted by club-health.eu and the 
safe-partying ‘quality nights’ labels promoted by the 
European project ‘Party+’. A review of the availability of 
three nightlife interventions: the provision of information 
materials, outreach work and first aid, indicates, however, 
that for most countries activity in this area is still limited 
(Figure 3.2).   FIGURE 3.2
I  Preventing infectious diseases: hepatitis C treatment needs more attention
Drugs users, and particularly injecting drug users, are 
at risk of contracting infectious diseases through the 
sharing of drug use material and through unprotected 
sex. Preventing the transmission of HIV, viral hepatitis 
and other infections is therefore an important objective 
for European drug policies. For injecting opioid users, the 
effectiveness of substitution treatment in this area has 
been demonstrated in several recent reviews and appears 
to increase when combined with needle and syringe 
programmes. 
Availability of specific interventions in nightlife settings  
(expert ratings, 2011)
First Aid
Outreach work
Drug-related information
FIGURE 3.2
 Full/extensive   Limited/rare   Not available   No data
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also suggest that getting infected users into hepatitis C 
antiviral treatment may reduce transmission of the virus. 
Despite this, and growing evidence supporting its effective 
use with injecting drug users, relatively few are currently 
receiving hepatitis C antiviral treatment in Europe. 
I  Preventing drug-related deaths: a major public health challenge
Reducing drug overdoses and other drug-related deaths 
remains a major challenge for public health policy in 
Europe. Being in drug treatment, particularly opioid 
substitution treatment, significantly reduces the mortality 
risk of drug users, and improving access to, and retention 
in treatment can be viewed as an important overdose 
prevention measure. Overdose risks, however, are known 
to increase for opioid users on leaving prison and some 
forms of treatment, probably due to reduced levels of 
tolerance. One innovative approach to addressing these 
risks is to make the opioid antagonist drug naloxone more 
widely available. Five countries report pilot projects or 
programmes that provide take-home naloxone to opioid 
users, their family members and carers (Figure 3.4). In 
the United Kingdom, a study showed that, with minimal 
training, healthcare professionals, including drug workers, 
could increase their knowledge, skills and confidence 
for managing an opioid overdose and administering 
naloxone. 
The number of syringes distributed through specialised 
programmes has increased from 34.2 million in 2005 to 
46.3 million in 2011 in the 23 countries providing national 
data for both years. In the 11 countries for which recent 
estimates of the number of injecting drug users are 
available, specialised programmes distributed an average 
of 127 syringes per injecting drug user in 2011, ranging 
from less than 50 to more than 300 syringes per user 
(Figure 3.3).  FIGURE3.3
A safe and effective vaccine exists to prevent the spread of 
hepatitis B virus (HBV), and 25 European countries have 
incorporated it into national vaccination programmes. 
Sixteen countries also report targeted HBV vaccination 
programmes for injecting drug users. For hepatitis C, 
for which a vaccine does not exist, similar prevention 
measures as for HIV transmission apply. However, in 
some European countries, initiatives directed at testing 
and counselling injecting drug users about hepatitis C 
are still limited and poorly funded. Modelling studies 
FIGURE 3.3 FIGURE 3.4
Countries with take-home naloxone programmes and supervised 
drug consumption facilities in Europe
Interventions
 Drug consumption facilities (DCF)  
 Take-home naloxone programmes   Both interventions  
 No data  9  Number of DCF
NB: Data displayed as point estimates and uncertainty intervals.
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I  Opioid users: substitution treatment  is the first choice
The most common treatment for opioid dependence in 
Europe is substitution treatment, typically integrated with 
psychosocial care and provided at specialised outpatient 
centres or by general practitioners. Methadone is the most 
commonly prescribed medication, received by up to three-
quarters of clients, while buprenorphine is prescribed 
to most of the remaining clients, and is the principal 
substitution medication in five countries (Figure 3.6). Less 
than 5% of all substitution treatments in Europe rely on 
the prescription of other substances, such as slow-release 
morphine or diacetylmorphine (heroin).   FIGURE 3.6
The majority of countries report distribution of information 
on overdose risk to problem drug users. Overdose risk 
assessment by trained drug or health workers can also 
assist in the early identification of high-risk individuals, 
while supervised drug consumption facilities can reach 
groups of marginalised drug users. Such facilities exist 
in six countries, and may contribute to the prevention of 
overdose deaths and to reducing the impact of non-fatal 
overdoses.    FIGURE3.4
I  More than a million Europeans  in drug treatment
It is estimated that at least 1.2 million people received 
treatment for illicit drug use in Europe during 2011. Opioid 
users represent the largest group undergoing treatment, 
while data on treatment entries (Figure 3.5) suggest that 
cannabis and cocaine users are likely to be the second and 
third largest groups, although with differences observable 
between countries.  FIGURE 3.5
Psychosocial interventions, opioid substitution and 
detoxification are the main drug treatment modalities 
in Europe, and most treatment is provided in outpatient 
settings, such as specialised centres, general practitioners’ 
surgeries and low-threshold facilities. A significant, 
although decreasing proportion of drug treatment is also 
provided in inpatient settings. 
FIGURE 3.5 FIGURE 3.6
Numbers of clients entering specialised drug treatment 
services, by primary drug
Predominant opioid substitution medication by number of clients
 Methadone   Buprenorphine   Methadone = buprenorphine  
 No data
NB: Buprenorphine includes the buprenorphine–naloxone combination. Heroin  Cocaine  Cannabis  
 Other stimulants  Other drugs  No information
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Lithuania (Figure 3.7). Long waiting times of between 
one and six months were reported by five countries, while 
waiting times exceeding six months were reported in 
Bulgaria and Greece. However, following HIV outbreaks 
among heroin injectors in 2010, Greece has recently 
scaled-up the provision of substitution treatment and 
waiting times have been reduced.     FIGURE 3.7
I  Other treatment for opioid users:  available in all countries
Treatment without substitution medication is provided 
to opioid users in all European countries. It can take 
place in outpatient and residential facilities, and includes 
psychosocial interventions, such as cognitive-behavioural 
therapy, therapeutic communities and other approaches. 
Treatment is sometimes preceded by a detoxification 
programme, which provides pharmaceutical assistance 
to manage physical withdrawal symptoms. Cognitive-
behavioural interventions have shown some effectiveness 
with opioid users, but evidence is not sufficiently robust 
to allow the identification of which intervention is the 
most effective. There is no conclusive evidence on the 
effectiveness of drug-free therapeutic communities. 
The coverage of treatment approaches other than 
substitution medication, ranges from 5% to over 50% of all 
problem opioid users across the nine countries providing 
The available evidence supports opioid substitution 
treatment, combined with psychosocial care, for keeping 
patients in treatment, as well as reducing illicit opioid 
use and drug-related harms and mortality. Methadone, 
buprenorphine and diacetylmorphine have been shown 
to be effective in interrupting the cycle of intoxication and 
withdrawal, and thereby helping patients to stabilise and 
to comply with other types of interventions (treatment 
for HIV/AIDS and hepatitis, for example). Substitution 
treatment has also been shown to improve quality of life 
and facilitate social reintegration.
The total number of opioid users receiving substitution 
treatment in Europe is estimated at 730 000 in 2011, up 
from 650 000 in 2008. This probably represents about 
50% of problem opioid users in Europe, an estimated 
coverage rate that is comparable to those reported for 
Australia and the United States. In Europe, however, large 
national differences in coverage rates exist, with the lowest 
estimated rates (3–20%) reported in Latvia, Slovakia and 
FIGURE 3.7 FIGURE 3.8
Percentage of problem opioid users receiving drug treatment 
(estimate) 
Percentage of problem opioid users in substitution treatment 
(estimate)
 Opioid substitution treatment   Other forms of treatment
NB: Data displayed as point estimates and uncertainty intervals.
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I  Amphetamines treatment:  geographical differences
Psychosocial interventions provided in outpatient 
drug services are the primary treatment options for 
amphetamines users. Both cognitive-behavioural therapy 
and contingency management, sometimes in combination, 
appear to be associated with positive results. Several 
drugs have been studied to treat amphetamine and 
methamphetamine dependence, but robust evidence has 
yet to be provided for any pharmacological therapy. 
The treatment options available for amphetamines users in 
Europe differ considerably between countries. Specifically 
tailored treatment programmes are primarily available in 
countries with a long history of treating amphetamines 
users (Figure 3.10). In addition, Bulgaria and Hungary 
report that plans exist to implement specific treatment 
programmes for amphetamine users in the near future.      
FIGURE  3.10
sufficient data (Figure 3.8). All of these countries have 
coverage rates for all type of treatments for problem  
opioid users exceeding 40%.   FIGURE3.8
I  Treatment for cocaine users:  specific programmes exist
The primary treatment options for cocaine dependence  
are psychosocial interventions, with contingency 
management appearing to be the intervention with the 
highest efficacy. In terms of medications, dopamine 
agonists and antipsychotic drugs may be effective  
in reducing cocaine use. 
Although those with cocaine problems may be seen in 
generic treatment services, specialised programmes 
for cocaine or crack cocaine users exist in 12 countries 
(Figure 3.9), including the countries with the highest levels 
of cocaine use. In some countries, such programmes target 
socially integrated cocaine users who may be reluctant to 
attend other services. In Denmark and Austria, treatment 
for cocaine users is also provided in polydrug use 
programmes. Bulgaria, Malta and the Netherlands report 
that plans exist to provide specific treatment programmes 
in the near future. Specific guidelines for treating cocaine 
users have been developed in Denmark, Germany and the 
United Kingdom.      FIGURE  3.9
FIGURE 3.9 FIGURE 3.10
Availability of specific treatment programmes for amphetamines 
users (expert ratings, 2011) 
Availability of specific treatment programmes for cocaine  
users (expert ratings, 2011)
 Full/extensive   Limited/rare   None   No data  Full/extensive   Limited/rare   None   No data
54
European Drug Report 2013: Trends and developments
I  GHB: treatment options explored
Dependence on gamma-hydroxybutyrate (GHB) is a 
recognised clinical condition, with a potentially severe 
withdrawal syndrome following regular or chronic use. 
To date, research has focused on the description of that 
syndrome and the related complications, which can be 
difficult to recognise in emergency cases. As yet, standard 
protocols have not been devised for the treatment of GHB 
withdrawal syndrome, although investigations are being 
carried out in the Netherlands into controlled detoxification 
using medicinal products containing GHB. 
I  Social reintegration: the missing element?
Data on clients who entered specialised drug treatment 
in 2011 show that about half of them were unemployed 
(47%) and almost one in ten lacked stable accommodation 
(9%). Low educational attainment is also common among 
this group, with 36% having completed only primary 
education, and 2% not even achieving this level of 
education.
Social reintegration services, which include improvement 
of social skills, promoting education and employability, 
and meeting housing needs, may either be provided 
alongside or after completion of drug treatment. While 
most countries report the existence of such reintegration 
services (Figure 3.12), levels of provision are generally 
insufficient in relation to needs. In addition, access to 
services is often conditional, for example, it may be 
dependent on drug-free status or stable housing, and this 
may exclude some of those most in need of support. 
The success of social reintegration measures often 
relies on effective collaboration between different types 
of support services. This topic was explored in a recent 
EMCDDA survey, where 17 out of 28 countries reported 
the existence of some form of partnership agreements 
between drug treatment agencies and services offering 
support in areas such as housing and employment.       
FIGURE  3.12
I  Cannabis treatment: multiple approaches
In Europe, treatment for cannabis users spans a broad 
range of approaches including Internet-based treatment, 
brief interventions, multidimensional family therapy, 
cognitive-behavioural therapy and other structured 
psychosocial interventions in outpatient or inpatient 
settings. The criminal justice system, accident and 
emergency rooms, and mental health treatment units 
are important sources of referral in some countries. The 
availability of cannabis treatment evaluation studies 
has increased in recent years with, for example, a recent 
meta-analysis on multidimensional family therapy showing 
positive results in terms of reducing substance use and 
retention in treatment. Research is also being conducted 
on pharmaceuticals that may support psychosocial 
interventions. For example, rimonabant, an agonist, has 
shown positive results for reducing acute physiological 
problems linked to cannabis smoking.
In 2011, more than half of European countries reported 
that specific cannabis treatment programmes were 
available (Figure 3.11), while Bulgaria, Cyprus, Hungary 
and Poland are planning to introduce programmes  
in this area.       FIGURE  3.11
FIGURE 3.11
Availability of specific treatment programmes for cannabis 
users (expert ratings, 2011)
 Full/extensive   Limited/rare   None   No data
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Drug-related services provided in European prisons cover a 
range of interventions which include: information provision, 
counselling and treatment, harm-reduction measures and 
preparation for release. Screening for infections, principally 
HIV, is frequently offered at prison entry, and in a few 
countries also upon release. HCV screening, however, is 
not always included in existing testing programmes. The 
provision of clean injecting equipment in prison settings 
is rare, with only four countries reporting that syringes are 
available in at least one prison.
I  Services for prisoners: still underdeveloped 
Prisoners report higher overall rates of drug use than the 
general population and more harmful patterns of use, 
as indicated by recent studies reporting that between 
5% and 31% of prisoners have ever injected drugs. On 
admission to prison, most users reduce or stop consuming 
drugs. Illicit drugs do, however, find their way into many 
prisons, and some prisoners continue or initiate use during 
incarceration. 
As prisoners with drug problems often have multiple 
and complex health needs, which may require multi-
disciplinary and specialist input from medical services, 
needs assessment upon prison entry is an important 
intervention. Most countries have now established 
interagency partnerships, between prison health 
services and providers in the community, to deliver 
health education and treatment interventions in prison, 
but also to ensure continuity of care upon prison entry 
and release. Seven European countries have assigned 
prison health to fall under the responsibility of the health 
ministries. Overall, however, the provision of drug services 
in prisons still often lags behind that available to the wider 
community, despite a general commitment to the principle 
of equivalence of care.
FIGURE 3.12
Availability of social reintegration programmes for drug users in treatment (expert ratings, 2010)
Vocational training  
programmes
Housing programmes
 Full/extensive   Limited/rare   None   No data
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drug legislation. These include two main types: dedicated 
‘drug squads’ and organised crime agencies with a specific 
drug supply reduction mandate. 
At least one of these two types of organisations exists in 26 
countries, which reported a total of more than 1 000 units 
with specific drug law enforcement mandates (Figure 3.14). 
The number of law enforcement officers specialising in 
work with illicit drugs was estimated for 23 countries, 
amounting to a minimum of 17 000 specialised officers, 
mostly from police forces. Although the numbers reported 
are not always directly comparable, specialised officers can 
be estimated to represent between 0.2% and 3.3% of all 
law enforcement officers at national level. 
The majority of drug squads and organised crime agencies 
with a drug supply reduction mandate are affiliated with 
police forces, although a small number are also attached 
to customs services. Furthermore, 11 countries report 
the existence of multi-agency cooperation, usually in the 
Opioid substitution treatment now exists in prisons in 
most countries, but its introduction has been slower than 
in the community. A recent estimate suggests that at least 
74 000 prisoners have received this treatment during 
the year, although levels of provision vary considerably 
between countries. Restrictions may also exist, for 
example, some countries only provide substitution 
treatment to prisoners who were already receiving it prior 
to incarceration (Figure 3.13). FIGURE  3.13
I  Drug supply reduction: a shift away  from drug squads
Although demand reduction interventions are commonly 
documented, systematic data collection on supply 
reduction activities is much rarer, despite the fact that 
such activities often consume the greater share of national 
drug budgets. Drug law enforcement is a key component 
of supply reduction and the EMCDDA has recently initiated 
a pilot project to improve description and understanding 
of the organisation of activities in this area. A starting 
point for this has been a mapping of formally established 
law enforcement organisations that have as their primary 
mission the detection and investigation of breaches of 
FIGURE 3.13 FIGURE 3.14
Availability of opioid substitution treatment in prisons
 Both continuation and initiation of treatment  
 Only continuation of treatment
 No cases reported   Not available
Types of specialised drug law enforcement organisations in Europe
 Dedicated drug squads   Serious organised crime units
 Both   Other  No data
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form of joint police and customs squads or units, but also 
sometimes including other agencies such as coastguards 
or border control agencies. These, however, amounted to 
only 42 out of the more than 1 000 bodies identified. 
Although 21 countries report the existence of dedicated 
drug squads, data suggest that overall, this form of 
specialised unit is declining in Europe, in favour of the 
establishment of more comprehensive ‘serious and 
organised crime’ agencies. This mirrors, to some extent, 
developments at EU level, with drug supply being 
increasingly considered as one of several interlinked 
dimensions of the fight against organised crime by both 
Europol’s Serious and Organised Crime Threat Assessment 
and within the European Council’s policy cycle for 
organised and serious international crime.   FIGURE  3.14
 The number of law  
 enforcement officers  
 specialising in work with  
 illicit drugs was estimated  
 for 23 countries, amounting  
 to a minimum of 17 000  
 specialised officers 
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Monitoring drug policies
Key policy dimensions that can be monitored at 
European level include: drug laws and drug law 
offences, national drug strategies and action plans, 
policy coordination and evaluation mechanisms, as 
well as drug-related budgets and public expenditure. 
Data are collected via two EMCDDA networks: the 
national focal points and the legal correspondents. 
Data and methodological notes on drug law 
offences can be found in the Statistical bulletin, and 
comprehensive information on European drug policy 
and law is available online. 
I Drug laws: a common framework
Drug control policies in Europe work in the overall context 
provided by the international control system built on 
three United Nations Conventions. This system sets out 
a framework for controlling the production, trade and 
possession of over 240 psychoactive substances, most of 
which have a recognised medical use. The Conventions 
oblige each country to treat unauthorised supply as a 
criminal offence. The same is required for possession 
of drugs for personal use, but subject to a country’s 
‘constitutional principles and the basic concepts of 
its legal system’. This clause has not been uniformly 
interpreted by European countries, and this is reflected in 
different legal approaches in this area.
Drug policies
In Europe, it is the responsibility 
of national governments and 
parliaments to adopt the legal, 
strategic, organisational and 
budgetary frameworks necessary 
to respond to drug-related problems, 
while EU drugs legislation and multi-
annual strategies and action plans 
provide a framework for coordinated 
action. Together, these elements build 
the drug policies that allow countries 
to develop and implement the drug 
demand and supply reduction 
interventions reviewed in this report.
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Sentencing practices shed some light on the 
implementation and actual outcomes for drug use or 
personal possession offences in Europe. In 2009, an 
EMCDDA data collection indicated that many countries 
give fines, warnings or community work orders for 
possession of drugs for personal use, although some 
central and eastern European countries, such as Bulgaria, 
Poland, Romania, Slovakia and Croatia, were more likely to 
use suspended prison sentences.
I Supply of drugs: variations in penalties
Illegal drug supply is always a crime in Europe, but the 
maximum possible penalties vary considerably. In some 
countries, a supply offence may be subject to a single 
wide penalty range (up to life in prison). Other countries 
differentiate between minor and major supply offences, 
determined by factors such as the quantity of drugs 
found, with corresponding maximum penalties. Another 
approach, found in 14 of the 30 countries considered 
here, is to vary penalties according to the drug involved 
(Figure 4.2).    FIGURE 4.2
Reports of drug supply offences have increased by one-
quarter since 2006, reaching more than 225 000 cases 
in 2011. As for possession offences, cannabis accounted 
for the majority of reported supply offences. Cocaine, 
heroin and amphetamines, however, accounted for a larger 
share of offences for supply than for personal possession 
(Figure 4.3).   FIGURE 4.3
I  Possession of drugs for personal use:  moving away from prison sentences
In most European countries, the possession of drugs 
for personal use (and sometimes drug use) is a criminal 
offence punishable by a prison sentence. In some 
countries, however, it can only be punished by non-
criminal sanctions such as fines or suspension of driving 
licence. An additional factor is the drug involved. In 
two-thirds of European countries, national laws prescribe 
the same penalty for a personal possession offence, 
regardless of the substance. For the remaining countries, 
the possible penalty varies according to the substance. 
Overall, from around 2000, there has been a general trend 
across Europe to reduce the possibility of imprisonment for 
possession of drugs for personal use. Some countries have 
changed their legislation to remove prison penalties (for 
example Portugal, Slovenia, Bulgaria and, most recently, 
Croatia), while others have issued national directives to 
police or prosecutors to use sanctions other than prison. 
The approach taken in Portugal has received considerable 
international attention. The measures introduced in 2001 
reduced the emphasis on punishment and direct drug 
users to a network of ‘commissions for dissuasion of drug 
addiction’, managed by the ministry of health. 
In most European countries, the majority of reports of 
drug law offences relate to drug use or possession for use; 
overall in Europe, these totalled more than a million in 
2011, a 15% increase compared to 2006. More than three-
quarters of these offences involve cannabis (Figure 4.1). 
Reported offences related to drug use or possession for use in Europe, trends and breakdown by drug (main drugs)
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also indicated that the average sentences differed by 
type of drug, even in those countries where the drugs are 
viewed equally under the law.
Sentencing statistics for a selected number of countries 
from 2009 show that a supply offence was more likely 
to receive a prison sentence than one for possession for 
use. However, maximum sentences were rarely or never 
imposed, while average prison sentences were short and 
often suspended, suggesting that only a small number of 
offenders were considered to be major traffickers. Results 
Penalties for drug law offences: variation by drug National drug strategies and action plans, availability and scope
FIGURE 4.2 FIGURE 4.4
 Combined licit and illicit drug strategy  
 Illicit drug strategy   No national drug strategy
NB: While the United Kingdom has an illicit drug strategy, both Wales and 
Northern Ireland have combined strategies which include alcohol.
 Same penalties for all drugs
Penalties vary by drug for:  
 Supply offences  Personal possession offences  
 Both offences types
Reported offences related to drug supply in Europe, trends and breakdown by drug (main drugs)
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other countries, coordination at regional or local level is 
often directly supervised by the national bodies.
In recent years, both the European Union and an increasing 
number of countries have performed a final evaluation of 
their drug strategy or action plan (Figure 4.5). The aim is 
generally to assess the level of implementation achieved, 
as well as the changes in the overall drug situation, in 
order to inform the development of the next strategy. 
Across Europe, most evaluations are internal, performed 
by the agency or institution responsible for the plan, but 
an increasing number of countries have commissioned 
joint or external evaluations. Currently, most European 
countries have plans to undertake a final evaluation of 
their ongoing drug strategy.   FIGURE 4.5
I National drug strategies: a European standard
Since the late 1990s it has become established practice 
for national governments in Europe to adopt drug 
strategies and action plans. These time-limited documents 
contain a set of general principles, objectives and 
priorities, specifying actions and the parties responsible 
for their implementation. Currently, all countries have a 
national drug strategy or action plan, except Austria which 
has provincial plans. Five countries have adopted national 
strategies and action plans that cover both licit and illicit 
drugs (Figure 4.4).     FIGURE 4.4
I  Supporting drug strategies: coordination  and evaluation mechanisms 
In parallel with the development of national drug 
strategies, countries have also set up mechanisms to 
coordinate the implementation of their drug policy. At 
national level, most countries now have an inter-ministerial 
committee on drugs, supplemented by a national drug 
coordination body, which is responsible for the day-to-day 
management of activities. In 14 countries, it is attached 
to the ministry of health, while elsewhere, it is attached to 
the office of government or the prime minister’s office, to 
the ministry of interior or to other ministries. Twenty-two 
countries also report having a formally appointed national 
drug coordinator, who is often the head of the national 
coordination body. National coordinators meet at EU level.
At the regional or local level, drug coordination agencies, 
drug coordinators, or both exist in most countries. In 
addition, in some countries, particularly those with a 
federal structure, vertical coordination bodies promote 
cooperation between the national and the local level. In 
Cumulative number of countries with an evaluated national 
drug strategy
FIGURE 4.5 FIGURE 4.6
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 Most countries now have 
 an inter-ministerial committee 
 on drugs, supplemented 
 by a national drug coordination 
 body, which is responsible 
 for the day-to-day management 
 of activities 
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I Economic evaluation: the need for better data
Economic evaluation, by exploring the comparative costs 
and benefits of alternative courses of action, can be an 
important tool for policy evaluation. However, the quantity 
and quality of information available on drug-related 
public expenditure in Europe remains very limited, and 
this represents a major obstacle for cost-effectiveness 
analysis. There has, nevertheless, been an increase in the 
number of countries that have attempted to estimate, at 
least once over the last decade, how much government 
was spending on drug policy. These countries report 
expenditure estimates ranging from 0.01% to 0.7% of GDP 
(Figure 4.6), although comparisons between countries are 
difficult to make as the scope and quality of the estimates 
vary greatly. Despite these limitations, however, it appears 
from the information available that drug supply reduction 
activities account for the largest share of drug-related 
public expenditure in most countries.    FIGURE 4.6:
Europe, like many other parts of the world is still facing 
the consequences of the recent economic downturn. 
These can include negative economic growth, increasing 
unemployment rates, particularly among young people, 
and reductions in government spending. Available budgets 
for health, public order and safety measures may have 
been affected, and this is where most drug-related public 
expenditure originates. Currently, the extent of the fiscal 
consolidation or austerity measures and their impact 
appear to differ considerably between European countries. 
Latvia, Lithuania and Estonia were among the countries 
with the largest reduction in public expenditure. Cuts in 
drug-related programmes and services are also now  
being reported by a number of European countries.
 National data presented here are  
 drawn from and are a subset of  
 the EMCDDA Statistical bulletin  
 2013, where further data, years,  
 notes and meta-data are available 
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Annex: national data tables
OPIOIDS
Problem opioid 
use estimate
Treatment demand indicator, primary drug
Clients in 
substitution 
treatment
Opioid clients as %  
of treatment entrants
% opioid clients injecting  
(main route of administration)
All entrants First-time entrants All entrants
First-time 
entrants
Country cases per 1 000 % (count) % (count) % (count) % (count) count
Belgium – 36.8 (2 176) 18 (403) 19.7 (399) 16.3 (60) 17 701
Bulgaria – 79.3 (1 877) 93.2 (275) 85.9 (1 300) 84.2 (223) 3 452
Czech Republic 1.2–1.3 19.4 (1 791) 9.9 (443) 86.3 (1 528) 83.1 (359) 5 200
Denmark – 17.5 (663) 7.1 (102) 33.9 (193) 23 (20) 7 600
Germany 2.9–3.4 44.3 (31 450) 19.2 (3 576) 36.2 (13 827) 33.2 (1 491) 76 200
Estonia – 91.4 (486) 80.4 (131) 84.5 (410) 84 (110) 1 076
Ireland 6.2–8.1 57.9 (4 930) 39 (1 457) 31 (1 488) 22.9 (327) 8 729
Greece 2.5–3.0 80.6 (4 693) 73.4 (1 886) 41.3 (1 930) 38.7 (729) 6 783
Spain 1.1–1.3 34.3 (18 374) 18.2 (4 881) 15.8 (2 756) 10.2 (481) 82 372
France – 40.7 (14 987) 20.2 (2 042) 17.7 (2 097) 12.3 (226) 145 000
Italy 4.3–5.4 55.3 (23 416) 42.4 (9 706) 57.5 (12 566) 50.5 (4 603) 109 987
Cyprus 1.3–2.0 36.7 (365) 10.8 (48) 52.6 (191) 46.8 (22) 188
Latvia 5.0–9.9 52.9 (1 044) 34.1 (126) 93.3 (935) 88.4 (107) 277
Lithuania 2.3–2.4 – 72.1 (181) – 98.6 (136) 798
Luxembourg 5.0–7.6 67.4 (151) – 58.9 (89) – 1 228
Hungary 0.4–0.5 6.8 (325) 2.3 (75) 66.8 (203) 49.3 (34) 639
Malta 6.9–8.2 78.7 (1 434) 45.4 (83) 62.5 (893) 59 (49) 1 107
Netherlands 1.6–1.6 12.8 (1 674) 6 (461) 8.9 (91) 16 (46) 10 085
Austria 5.2–5.5 64.5 (2 426) 41.3 (566) 42.2 (987) 26.8 (146) 16 782
Poland – 48.2 (643) 14.7 (53) 77 (488) 46.2 (24) 2 200
Portugal – 70.1 (2 637) 54.4 (980) 15.4 (147) 13.1 (80) 26 531
Romania – 35 (648) 29.6 (339) 91.5 (590) 90.2 (305) 742
Slovenia – 86.6 (451) 74.9 (155) 56.8 (256) 49.7 (77) 3 557
Slovakia 1.0–2.5 33.7 (691) 22.7 (217) 75.7 (514) 63.1 (137) 500
Finland – 62.2 (898) 43.8 (109) 81.8 (719) 66.7 (72) 2 000
Sweden – 24.8 (1 541) 16.5 (255) 55.7 (857) 26.6 (69) 3 115
United Kingdom 8.0–8.6 59.3 (68 112) 40 (18 005) 33.2 (22 081) 29.2 (5 156) 177 993
Croatia 3.2–4.0 80.9 (6 198) 29.8 (343) 74.5 (4 530) 53.3 (171) 4 074
Turkey 0.2–0.5 70.3 (1 488) 64.7 (701) 50.9 (746) 48 (333) 8 074
Norway 2.1–3.9 37.5 (2 884) – 73.1 (160) – 6 640
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COCAINE
Prevalence estimates Treatment demand indicator, primary drug
General population School population
Cocaine clients as % of 
treatment entrants
% cocaine clients  
injecting (main route  
of administration)
Lifetime, 
adult
(15–64)
Last 12 
months,
young adult
(15–34)
Lifetime, 
students
(15–16)
All entrants First-time entrants All entrants
First-time 
entrants
Country % % % % (count) % (count) % (count) % (count)
Belgium – 2 4 12.9 (764) 13.6 (304) 6.0 (37) 1.2 (3)
Bulgaria 1.7 1.5 3 0.8 (20) 1.4 (4) 30 (3) 0 (0)
Czech Republic 1.4 1.1 1 0.3 (30) 0.3 (14) 3.4 (1) 0 (0)
Denmark 4.4 2.5 2 5.1 (193) 5.8 (84) 10.1 (17) 0 (0)
Germany 3.3 1.8 3 5.9 (4 212) 6.2 (1 164) 19.8 (3 007) 8.7 (256)
Estonia – 1.3 – – – – –
Ireland 6.8 2.8 3 10 (850) 13.3 (496) 1.3 (11) 0.4 (2)
Greece 0.7 0.2 1 4.3 (248) 4.2 (109) 19 (47) 10.1 (11)
Spain 8.8 3.6 3 41.4 (22 131) 45.3 (12 148) 2.3 (480) 1.4 (167)
France 3.66 1.85 4 6.9 (2 544) 5.1 (519) 10.2 (215) 4.4 (21)
Italy 4.2 1.3 2 24.3 (10 271) 30.3 (6 938) 5.3 (516) 4.1 (273)
Cyprus 3 2.2 4 10.1 (100) 7 (31) 1 (1) 0 (0)
Latvia 1.5 0.3 4 0.4 (7) 0.3 (1) 0 (0) 0 (0)
Lithuania 0.5 0.3 2 – 0.8 (2) – 0 (0)
Luxembourg – – – 18.3 (41) – 39 (16) –
Hungary 0.9 0.4 2 1.6 (78) 1.6 (52) 2.7 (2) 0 (0)
Malta 0.4 – 4 12.5 (228) 28.4 (52) 24.8 (56) 17.6 (9)
Netherlands 5.2 2.4 2 24.6 (3 220) 20.3 (1 560) 0.3 (6) 0 (0)
Austria 2.2 1.2 – 6 (226) 7.6 (104) 7 (15) 3 (3)
Poland 1.3 1.3 3 1.3 (17) 2.2 (8) 0 (0) 0 (0)
Portugal 1.9 1.2 4 10.5 (397) 14.4 (259) 3.6 (8) 1 (2)
Romania 0.3 0.2 2 1.2 (22) 1.6 (18) 4.8 (1) 5.9 (1)
Slovenia – – 3 3.5 (18) 3.9 (8) 44.4 (8) 25 (2)
Slovakia 0.6 0.4 2 0.8 (17) 1.6 (15) 0 (0) 0 (0)
Finland 1.7 0.6 1 0.1 (1) 0 (0) – –
Sweden 3.3 1.2 1 1.5 (91) 1.7 (27) 0 (0) 0 (0)
United Kingdom 9.6 4.2 3 12.3 (14 077) 16 (7 185) 2.1 (284) 1 (68)
Croatia 2.3 0.9 2 1.6 (126) 2.6 (30) 1.7 (2) 3.6 (1)
Turkey – – – 2.2 (46) 2.3 (25) 2.2 (1) 4 (1)
Norway 2.5 0.6 1 1 (78) – 25 (2) –
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AMPHETAMINES
Prevalence estimates Treatment demand indicator, primary drug
General population School population
Amphetamines clients as % of 
treatment entrants
% amphetamines clients 
injecting (main route  
of administration)
Lifetime,  
adult  
(15–64)
Last 12 
months,
young adult
(15–34)
Lifetime, 
students
(15–16)
All entrants First-time entrants All entrants
First-time 
entrants
Country % % % % (count) % (count) % (count) % (count)
Belgium – – 5 9.8 (581) 11.2 (250) 9.1 (50) 5 (12)
Bulgaria 2.1 2.1 6 1.4 (33) 1.7 (5) 0 (0) 0 (0)
Czech Republic 2.1 0.8 2 65.2 (6 008) 69.6 (3 122) 77.4 (4 601) 71.9 (2 210)
Denmark 6.2 2 2 9.5 (358) 10.3 (149) 3.1 (9) 0 (0)
Germany 3.7 1.9 4 11 (7 785) 15.2 (2 839) 1.7 (246) 0.7 (31)
Estonia – 2.5 3 – – 61.5 (8) 50 (4)
Ireland 4.5 0.8 2 0.6 (53) 0.9 (33) 6 (3) 6.3 (2)
Greece 0.1 0.1 2 0.1 (6) 0.1 (2) 0 (0) 0 (0)
Spain 3.3 1.4 2 1 (517) 1.2 (320) 0.6 (3) 0.6 (2)
France 1.69 0.46 4 0.3 (107) 0.3 (31) 14.9 (13) 0 (0)
Italy 1.8 0.1 1 0.1 (38) 0.1 (16) 0 (0) 0 (0)
Cyprus 0.7 0.7 4 0.2 (2) 0.2 (1) 50 (1) 0 (0)
Latvia 2.2 1.9 4 19.3 (380) 28.2 (104) 60.9 (206) 53.9 (48)
Lithuania 1.6 1.1 3 – 2 (5) – 60 (3)
Luxembourg – – – 0.4 (1) – 0 (0) –
Hungary 1.8 1.2 6 11.9 (567) 11 (354) 23.3 (130) 19.2 (67)
Malta 0.4 – 3 0.2 (3) – 33.3 (1) –
Netherlands 3.1 – 3 6.2 (818) 6.5 (499) 0.6 (3) 1 (3)
Austria 2.5 0.9 – 2.2 (83) 3.5 (48) 3.7 (3) 2.2 (1)
Poland 4.2 1.3 4 21.4 (285) 26.7 (96) 9.4 (25) 8.4 (8)
Portugal 0.9 0.4 3 0 (1) 0.1 (1) – –
Romania 0.1 0 2 0.6 (12) 0.9 (10) 0 (0) 0 (0)
Slovenia – – 2 0.4 (2) 0.5 (1) 50 (1) 0 (0)
Slovakia 0.5 0.7 2 38.2 (784) 41.9 (400) 32.1 (243) 25.4 (99)
Finland 2.3 1.6 1 14.1 (204) 11.6 (29) 78.6 (154) 64.3 (18)
Sweden 5 1.5 1 27.8 (1 728) 19.4 (301) 68.6 (1 137) 49.7 (149)
United Kingdom 11.5 1.4 2 3 (3 486) 3.6 (1 615) 22.1 (714) 16 (241)
Croatia 2.6 – 2 1 (80) 2.2 (25) 0 (0) 0 (0)
Turkey 0.3 – – 0.9 (18) 0.8 (9) 5.6 (1) 0 (0)
Norway 3.8 0.8 1 0 (0) – 75.1 (205) –
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ECSTASY
Prevalence estimates Treatment demand indicator, primary drug
General population School population Ecstasy clients as % of treatment entrants
Lifetime, 
adult
(15–64)
Last 12 months,
young adult
(15–34)
Lifetime, students
(15–16) All entrants
First-time  
entrants
Country % % % % (count) % (count)
Belgium – – 4.0 0.6 (38) 1 (23)
Bulgaria 1.7 1.6 4.0 0.3 (6) 0.3 (1)
Czech Republic 5.8 2.5 3.0 0.1 (6) 0.1 (3)
Denmark 2.1 0.8 1.0 0.3 (13) 0.5 (7)
Germany 2.4 1.0 2.0 0 (0) 0 (0)
Estonia – 2.3 3.0 – –
Ireland 6.9 0.9 2.0 0.6 (51) 0.6 (24)
Greece 0.4 0.4 2.0 0.2 (9) 0.2 (5)
Spain 3.6 1.4 2.0 0.2 (98) 0.2 (66)
France 2.4 0.4 3.0 0.3 (118) 0.2 (24)
Italy 1.8 0.1 1.0 0.3 (129) 0.5 (107)
Cyprus 2.0 1.0 3.0 0.3 (3) 0.2 (1)
Latvia 2.7 0.8 4.0 0.1 (2) 0 (0)
Lithuania 2.1 1.9 2.0 – –
Luxembourg – – – – –
Hungary 2.4 1.0 4.0 1 (50) 1.2 (38)
Malta 0.7 – 3.0 0.7 (13) 1.6 (3)
Netherlands 6.2 3.1 3.0 0.5 (69) 0.8 (58)
Austria 2.3 1.0 – 0.5 (19) 1.2 (16)
Poland 3.4 3.1 2.0 0.1 (1) 0.3 (1)
Portugal 1.3 0.9 3.0 0.1 (4) 0.2 (4)
Romania 0.7 0.4 2.0 0.5 (9) 0.6 (7)
Slovenia – – 2.0 0.2 (1) 0.5 (1)
Slovakia 1.9 0.9 4.0 0.1 (2) 0.2 (2)
Finland 1.8 1.1 1.0 0.3 (4) 0.8 (2)
Sweden 2.1 0.2 1.0 0.3 (17) 0.5 (7)
United Kingdom 8.6 2.8 3.0 0.2 (229) 0.3 (141)
Croatia 2.5 0.5 2.0 0.3 (23) 0.5 (6)
Turkey 0.1 0.1 – 0 (1) 0.1 (1)
Norway 1.0 0.6 1.0 0 (0) –
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CANNABIS
Prevalence estimates Treatment demand indicator, primary drug
General population School population Cannabis clients as % of treatment entrants
Lifetime, 
adult
(15–64)
Last 12 months,
young adult
(15–34)
Lifetime, students
(15–16) All entrants
First-time  
entrants
Country % % % % (count) % (count)
Belgium 14.3 11.2 24 31 (1 832) 48.2 (1 077)
Bulgaria 7.3 6 21 4.3 (101) 3.1 (9)
Czech Republic 24.9 16.1 42 13.2 (1 214) 18.7 (839)
Denmark 32.5 13.5 18 63.4 (2 397) 72.6 (1 048)
Germany 25.6 11.1 19 33 (23 418) 54.9 (10 236)
Estonia – 13.6 24 5.3 (28) –
Ireland 25.3 10.3 18 22.9 (1 951) 35.7 (1 336)
Greece 8.9 3.2 8 12.8 (746) 20.2 (518)
Spain 27.4 17 32 21 (11 210) 32.3 (8 653)
France 32.12 17.54 39 47.8 (17 621) 71.1 (7 193)
Italy 21.7 8 13 18.8 (7 957) 25.2 (5 781)
Cyprus 11.6 7.9 7 48.8 (485) 78.1 (346)
Latvia 12.5 7.3 24 11.8 (232) 19.8 (73)
Lithuania 11.9 9.9 20 – 3.6 (9)
Luxembourg – – – 12.9 (29) –
Hungary 8.5 5.7 19 69.4 (3 321) 77.3 (2 492)
Malta 3.5 1.9 10 6.7 (122) 20.8 (38)
Netherlands 25.7 13.7 26 48.3 (6 334) 58 (4 446)
Austria 14.2 6.6 – 22.5 (848) 41.8 (574)
Poland 17.3 17.1 23 23.5 (313) 44.4 (160)
Portugal 11.7 6.7 14 13.9 (525) 25.4 (457)
Romania 1.6 0.6 7 8.6 (160) 11.3 (130)
Slovenia – 6.9 23 8.4 (44) 18.8 (39)
Slovakia 10.5 7.3 27 19.2 (394) 27.3 (260)
Finland 18.3 11.2 11 13.4 (193) 32.9 (82)
Sweden 21.4 6.1 6 24.9 (1 550) 45.1 (699)
United Kingdom 31 12.3 21 20.3 (23 378) 32.4 (14 559)
Croatia 15.6 10.5 18 12.5 (957) 52.7 (607)
Turkey 0.7 0.4 – 17.1 (363) 22.1 (240)
Norway 14.6 7 5 20.3 (1 561) –
TABLE 5
70
European Drug Report 2013: Trends and developments
OTHER INDICATORS 
Drug-induced deaths 
(aged 15–64)
HIV diagnoses among 
injecting drug users 
(ECDC)
Injecting drug use 
estimate
Syringes distributed 
through specialised 
programmes
Country cases per million population (count)
cases per million 
population (count)
cases per  
1 000 population count
Belgium 19.6 (142) 1 (11) 2.5–4.8 938 674
Bulgaria 4.8 (24) 8.4 (63) – 643 377
Czech Republic 3.8 (28) 0.9 (9) 5.1–5.5 5 398 317
Denmark 49.8 (181) 1.8 (10) 2.8–4.7 –
Germany 17.9 (966) 1.1 (90) – –
Estonia 135.7 (123) 51.5 (69) – 2 130 306
Ireland 51.8 (159) 3.6 (16) – 1 097 000
Greece – 21.7 (245) 0.9–1.3 119 397
Spain 12.5 (392) 4.5 (148) 0.2–0.2 2 672 228
France 7.9 (331) 1.3 (87) – –
Italy 9.1 (362) 2.7 (161) – –
Cyprus 16.3 (9.66) 0 (0) 0.3–0.5 42
Latvia 7.9 (11) 40.4 (90) – 310 774
Lithuania 20.9 (43) 26.5 (86) – 181 408
Luxembourg 17.1 (6) 0 (0) 4.5–6.9 246 858
Hungary 2 (14) 0 (0) 0.8 648 269
Malta 17.3 (5) 0 (0) – 289 940
Netherlands 9.1 (101) 0.2 (4) 0.2–0.2 –
Austria 35.3 (201) 4.3 (36) – 4 329 424
Poland 8.4 (232) 1.2 (47) – 175 902
Portugal 2.7 (19) 5.8 (62) – 1 650 951
Romania 1 (15) 5 (108) – 901 410
Slovenia 16.9 (24) 0 (0) – 632 462
Slovakia 3.9 (15) 0.2 (1) 3.5–8.9 15 064
Finland 53.3 (189) 1.5 (8) – 3 539 009
Sweden 35.5 (217) 1.3 (12) – 244 493
United Kingdom 52.3 (2 153) 2.1 (131) 3.1–3.5 –
Croatia 19.8 (59) 0.7 (3) 0.4–0.6 340 357
Turkey 1.9 (93) 0.1 (5) – 0
Norway 73.1 (238) 2 (10) 2.5–3.6 2 639 000
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SEIZURES 
Heroin Cocaine Amphetamines Ecstasy
Quantity  
seized
Number of 
seizures
Quantity  
seized
Number of 
seizures
Quantity  
seized
Number of 
seizures
Quantity  
seized
Number of 
seizures
Country kg count kg count kg count tablets count
Belgium 140 2 176 7 999 3 263 112 2 699 64 384 838
Bulgaria 385 41 4 22 233 38 7 879 11
Czech Republic 5 34 16 44 1.20 3 13 000 15
Denmark 37 484 43 1 756 255 1 733 16 000 197
Germany 498 4 361 1 941 3 335 1 368 9 131 484 992 1 322
Estonia 0.048 5 1 34 42 215 11 496 44
Ireland 32 752 179 476 23 104 97 882 272
Greece 307 2 477 463 466 1.84 17 70 8
Spain 412 7 587 16 609 42 659 278 3 178 183 028 2 123
France 883 4 834 10 834 4 538 601 387 1 510 500 781
Italy 811 3 588 6 342 6 859 19 124 14 108 114
Cyprus 0.6 49 3 79 0.011 5 653 13
Latvia 0 329 81 25 0.1 29 3 592 13
Lithuania 11 234 10 23 13 46 303 5
Luxembourg 24 244 24 94 3 15 91 6
Hungary 3 22 13 108 24 483 270 22
Malta 4 39 5 86 0.50 1 2 171 30
Netherlands 400 – 10 000 – 1 074 – 1 059 534 –
Austria 65 640 139 970 13 383 45 780 90
Poland 51 – 78 – 395 – 75 082 –
Portugal 73 1 169 3 678 1 385 0.2 26 7 791 95
Romania 13 314 161 73 0.4 28 7 594 96
Slovenia 4 503 2 272 1 204 34 14
Slovakia 0 33 35.3 30 13.22 10 27 5
Finland 1.0 3 4 81 71 3 157 17 800 300
Sweden 21 314 89 618 168 3 542 17 060 189
United Kingdom 1 850 9 174 3 468 17 751 1 048 6 801 686 000 3 346
Croatia 33 185 4 142 15 372 2 898 75
Turkey 7 294 3 306 592 1 457 14 6 1 364 253 2 587
Norway 15 1 364 46 840 75 2 894 5 327 198
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TABLE 7
SEIZURES (continued)
Cannabis resin Herbal cannabis Cannabis plants
Quantity  
seized
Number of 
seizures
Quantity  
seized
Number of 
seizures
Quantity  
seized
Number of 
seizures
Country kg count kg count plants (kg) count
Belgium 5 020 5 156 5 095 21 784 337 955 (–) 1 070
Bulgaria 16.8 11 1 035 168 7 456 (4 658) 24
Czech Republic 2 24 441 508 62 817 (–) 240
Denmark 2 267 8 403 168 891 – (1 452) 710
Germany 1 748 7 285 3 957 27 144 – 133 650 1 804
Estonia 46 22 53 409 – (29.3) 25
Ireland 1 814 722 1 865 1 833 6 606 (–) 582
Greece 122 172 13 393 5 774 33 242 (–) 460
Spain 355 904 199 770 17 535 140 952 – (26 108) 1 436
France 55 641 85 096 5 450 12 155 73 572 (–) 2 146
Italy 20 258 6 244 10 908 4 007 1 008 215 (–) 1 208
Cyprus 1 33 76 758 86 (–) 27
Latvia 283 55 34 399 – (497) 7
Lithuania 168 31 43 311 – (–) 0
Luxembourg 2 171 11 833 81 (–) 5
Hungary 18 63 209 2 073 14 121 (–) 192
Malta 89 48 1.5 32 44 (–) 7
Netherlands 1 000 – 5 000 – 2 000 000 (–) –
Austria 75 1 197 621 5 272 – (219) 261
Poland – – 1 265 – 52 914 (–) –
Portugal 14 633 3 093 108 460 5 523 (–) 304
Romania 18 328 252 1 365 897 (–) 9
Slovenia 4.2 89 613 3 306 12 836 (–) 178
Slovakia 0.0 22 137 1 512 10 045 (18) 45
Finland 860 1 829 97 4 281 16 400 (42) 3 187
Sweden 950 7 465 264 5 272 – (–) 92
United Kingdom 19 665 15 094 22 402 149 411 626 680 (–) 16 672
Croatia 2 373 421 3 684 4 136 (–) 195
Turkey 21 141 8 192 55 251 43 217 – (–) 7 318
Norway 2 548 11 232 219 3 631 1 099 (214) 381
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About this report
The Trends and developments report presents  
a top-level overview of the drug phenomenon in Europe, 
covering drug supply, use and public health problems 
as well as drug policy and responses. Together with 
the online Statistical bulletin, Country overviews and 
Perspectives on drugs, it makes up the 2013 European 
Drug Report package. 
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the hub of drug-related 
information in Europe. Its mission is to provide the EU 
and its Member States with ‘factual, objective, reliable 
and comparable information’ on drugs, drug addiction 
and their consequences. Established in 1993, it opened 
its doors in Lisbon in 1995 and is one of the EU’s 
decentralised agencies. With a strong multidisciplinary 
team, the agency offers policymakers the evidence 
base they need for drawing up drug laws and strategies. 
It also helps professionals and researchers pinpoint 
best practice and new areas for analysis. 
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